Immunology
199.2K views | +4 today
Immunology
Teaching and Learning Immunology. Information you never would have searched for!
Your new post is loading...
Your new post is loading...
Suggested by Société Francaise d'Immunologie
July 9, 2019 1:33 PM
Scoop.it!

Skint8, a Novel B7 Family–Related Molecule, Negatively Regulates T Cell Responses | The Journal of Immunology

Skint8, a Novel B7 Family–Related Molecule, Negatively Regulates T Cell Responses | The Journal of Immunology | Immunology | Scoop.it
KEY POINTS Skint8 shares sequence and structural similarity to existing B7 family members. Skint8-Ig fusion protein inhibits T cell functions in vitro. Skint8-Ig alleviates experimental autoimmune encephalomyelitis in mice. Abstract Immune responses are tightly controlled by T cell costimulatory and coinhibitory molecules. In this study, we identify Skint8 as a new member of the T cell coinhibitory group, whose extracellular domains share significant homology with existing B7 family members. Skint8 mRNA is expressed in resting and activated B cells, monocytes, and CD4 T cells. The Skint8 putative receptor is expressed on activated CD4 and CD8 T cells, B cells, monocytes and dendritic cells. Recombinant Skint8–IgG Fc fusion protein inhibits T cell proliferation, activation, and cytokine production in vitro. In vivo administration of Skint8–IgG Fc reduces T cell activation and alleviates experimental autoimmune encephalomyelitis in mice. The findings broaden our understanding of the regulation of immune responses and may have implications for treating immune-related diseases. Footnotes This work was supported by grants from the National Institutes of Health (1R01AI123131) and the Connecticut Regenerative Medicine Research Fund (16-RMB-UCONN-02). The online version of this article contains supplemental material. Abbreviations used in this article: BTN butyrophilin BTNL BTN-like DC dendritic cell EAE experimental autoimmune encephalomyelitis qRT-PCR quantitative RT-PCR Skint selection and upkeep of intraepithelial T cells Skint8-Ig Skint8–IgG Fc Treg regulatory T cell. Received May 3, 2018. Accepted May 17, 2019. Copyright © 2019 by The American Association of Immunologists, Inc.
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies
July 5, 2019 9:12 AM
Scoop.it!

High-throughput analysis of the human thymic Vδ1 + T cell receptor repertoire

High-throughput analysis of the human thymic Vδ1 + T cell receptor repertoire | Immunology | Scoop.it
Data Descriptor...

Via Krishan Maggon
No comment yet.
Scooped by Gilbert C FAURE
June 25, 2019 4:14 AM
Scoop.it!

Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology | PNAS

Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology | PNAS | Immunology | Scoop.it
Significance TLS, which are clusters of lymphocytes and stromal cells observed at sites of chronic inflammation, play a key role in sustaining disease progression in autoimmune conditions. While the role of lymphocytes in these structures has been studied extensively, the role of fibroblasts, nonhematopoietic stromal cells, in the formation and maintenance of TLS has not been demonstrated. Here, we establish that, at sites of TLS establishment, resident fibroblasts expand and acquire immunological features in a process that is dependent on IL13 and IL22. Interference with this process or depletion of immunofibroblasts leads to involution of TLS, resulting in decreased immune-cell activation and resolution of tissue pathology, thus supporting the use of fibroblast-targeting strategies to treat TLS-associated autoimmune diseases. Abstract Resident fibroblasts at sites of infection, chronic inflammation, or cancer undergo phenotypic and functional changes to support leukocyte migration and, in some cases, aggregation into tertiary lymphoid structures (TLS). The molecular programming that shapes these changes and the functional requirements of this population in TLS development are unclear. Here, we demonstrate that external triggers at mucosal sites are able to induce the progressive differentiation of a population of podoplanin (pdpn)-positive stromal cells into a network of immunofibroblasts that are able to support the earliest phases of TLS establishment. This program of events, that precedes lymphocyte infiltration in the tissue, is mediated by paracrine and autocrine signals mainly regulated by IL13. This initial fibroblast network is expanded and stabilized, once lymphocytes are recruited, by the local production of the cytokines IL22 and lymphotoxin. Interfering with this regulated program of events or depleting the immunofibroblasts in vivo results in abrogation of local pathology, demonstrating the functional role of immunofibroblasts in supporting TLS maintenance in the tissue and suggesting novel therapeutic targets in TLS-associated diseases. The establishment of TLS (tertiary lymphoid structures) is a phenomenon associated with cancer, infection, and autoimmunity (1). Within peripheral tissue, in autoimmune conditions such as primary Sjögren’s syndrome (pSS), TLS form pathogenic hubs of acquired immune responses that are classically associated with a Th2 paradigm, ectopic autoantibody production, and the potential expansion of malignant autoreactive B cell clones (1). While principally composed of lymphocytes and dendritic cells, TLS organization is supported by a complex network of nonhematopoietic stromal cells. These include endothelial cells, lymphatic vessels, nerves, and immunofibroblasts that closely resemble the fibroblastic reticular cells (FRCs) that inhabit secondary lymphoid organs (SLOs). These populations form a network that is believed to support the organization and maintenance of the immune cells in TLS and have been deemed responsible for local disease resistance to lymphocyte depletion (2, 3). Elegant in vivo and in silico studies have revealed the heterogeneity of the stromal cell populations in SLOs (4) and demonstrated that interfering with the podoplanin (pdpn)+/Fibroblast activation protein 1 (FAP)+ network of immunofibroblasts profoundly affects immune cell homeostasis (5⇓–7). Similar data are not available in chronic autoimmune conditions where targeting the pathogenic microenvironment could be envisaged, alongside immune-cell biological therapy, to induce disease remission. During embryogenesis, innate lymphoid cells (ILCs) provide molecular cues for the activation of the resident mesenchyme in ICAM-1high, VCAM-1high organizer cells (8⇓–10). Thereafter, lymphocyte migration in the anlagen is responsible for the full differentiation of FRCs within distinct areas of an SLO. Within TLS, the molecular requirement for immunofibroblast specification is still debated (2), and this hampers the development of therapeutics aimed at targeting this population in humans. We and others have previously demonstrated that specific cytokines might support the acquisition of pathogenic features of resident fibroblasts (11⇓⇓⇓–15). However, a broader understanding of the signals involved in TLS mesenchymal specification is still missing, and definitive proof that targeting activated fibroblasts might interfere with TLS-associated disease is not available. Here, we provide evidence that immunofibroblasts in human and murine TLS are required to support local pathology and support the production of antinuclear antibodies (ANAs). We show that human TLS are underpinned by the formation of a network of immunofibroblasts that express pdpn and FAP and respond in vitro to stimulation with Th2 cytokines and IL22. In vivo, we demonstrate the presence of resident immunofibroblast progenitors at the sites of TLS establishment, whose development is initiated by IL13. We prove that leukocytes are dispensable for this early phase of priming but are later required for the expansion of the fibroblast network, in a process mediated by the expression of IL22 and LTα1β2. Finally, we show that targeting this microenvironment in vivo, either by depleting immunofibroblasts or interfering with their cytokine-dependent developmental pathway, is sufficient to induce abrogation of local pathology and silence the humoral autoantibody response. As such, we provide evidence that targeting immunofibroblasts, alongside lymphocytes, could be considered to achieve long-term remission in chronic inflammatory diseases. Results IL13 and IL22 Modulate the Phenotype and Proliferation of the TLS Immunofibroblasts in Salivary Glands of Patients with pSS. The establishment of TLS in the salivary glands of patients with pSS is supported by a fibroblast network that express pdpn and FAP, identified both by immunofluorescence (Fig. 1A and SI Appendix, Fig. S1) and flow cytometry (Fig. 1B). The development of this network in human samples, that is similar to the FRC network observed in the SLOs (16), correlates with the severity of CD45+ immune cell infiltration (SI Appendix, Fig. S1). Single-cell PCR analysis of the pdpn+ fibroblasts unveiled 2 separate clusters (1, 2). Cluster 1 was characterized by enrichment for FAP, ICAM-1, VCAM-1, and CD34 transcripts (Fig. 1C). Given the overlap between CD34 and ICAM-1/VCAM-1 expression, CD34 was used as a surrogate marker to sort CD34+ and CD34-PDPN+ cells, the former being ICAMhigh/VCAMhigh (SI Appendix, Fig. S1). Interestingly, sorted pdpn+CD34+ cells display enrichment for transcripts encoding for IL7 and B cell activation factor (BAFF) while pdpn+CD34− cells showed enrichment for transcripts encoding for CXCL13, CCL19, and CCL21 (Fig. 1D). These data suggest that, within the pdpn+ population in humans, 2 subpopulations of stromal cells are present that respectively support lymphocyte survival and organization within the TLS. Both populations were found to express receptors for TNFα, LTα1β2, IL4, and IL13, and for IL22, a cytokine that we previously demonstrated to be responsible for chemokine expression in TLS (12) (Fig. 1D and SI Appendix, Fig. S1). Fig. 1. TLS human fibroblasts are characterized by expression of pdpn, FAP, and adhesion molecules. (A) Immunofluorescence analysis of salivary gland biopsy from pSS patient stained for pdpn (red), FAP (green), and DAPI (blue). (Scale bar: 250 µm.) (B) viSNE plots of CD45−CD235a−CD11b−EpCAM−CD31− cells from pSS patients’ salivary gland biopsy tissue, analyzed by multicolor flow cytometry. Colors indicate cell expression level of labeled markers (pdpn, FAP, ICAM-1, and VCAM-1). (C) Principle component analysis (PCA) plot from pdpn+ single-cell PCR data. Data are shown for FAP, ICAM-1, VCAM-1, and CD34 in the 2 clusters identified by hierarchical clustering analysis. (D) viSNE plots of CD45−CD235a−CD11b−EpCAM−CD31− cells from pSS patients’ salivary gland biopsy tissue, analyzed by multicolor flow cytometry. Colors indicate cell expression level of labeled markers (CD34). Graphs show differential gene expression data for baff, il7, pdgfrα, cxcl12, pdgfrß, cxcl13, ccl19, ccl21, il4rα, and il22rα transcripts in FACS-sorted CD34+ and CD34−pdpn+ populations. Data are expressed as mean ± SD (n = 5); *P < 0.05; **P < 0.01; paired t test. (E) Expression of vcam1, icam1, and pdpn mRNA transcript levels in pSS fibroblasts stimulated in vitro with IL13, TNF, and LTα1β2 (n = 5). Relative quantitation (RQ) was calculated with unstimulated cells. *P < 0.05; **P < 0.01; one-way ANOVA. Data are represented as mean ± SD. (F) Analysis of the percentage of pSS fibroblasts positive for BrdU flow cytometry staining post in vitro stimulation with IL22, TNF, and LTα1β2 (n = 5). *P < 0.05; one-way ANOVA. Data are represented as mean ± SD. IL13 expression has been previously associated with autoimmunity (17⇓⇓⇓⇓–22). Interestingly, the in vitro challenge of human isolated fibroblasts with IL13 significantly increased the expression of VCAM-1 and, to a lesser extent, pdpn and ICAM-1 in synergy with TNFα and LTα1β2 (Fig. 1E). On the contrary, stimulation of the same fibroblasts with IL22 demonstrated the functional ability of this cytokine to induce cell proliferation (Fig. 1F). However, IL22 did not induce VCAM-1, ICAM-1, and pdpn (SI Appendix, Fig. S1). While a certain degree of variability was observed in the fibroblasts’ response to cytokines in vitro, our results suggested the possibility that cytokines belonging to different families exert different and complementary effects on the resident mesenchyme and cooperate with the TNFα family members toward the acquisition of an immune-pathogenic phenotype during TLS assembly. Immunofibroblast Activation and Expansion Are Observed During TLS Formation in a Murine Model of Induced Salivary Gland Inflammation. We took advantage of a previously described model of TLS assembly, characterized by formation of TLS upon salivary gland infection of wild-type (wt) mice with AdV5 (108–12 plaque-forming unit) (23). We demonstrated that progressive lymphocyte aggregation in the salivary glands upon infection (SI Appendix, Fig. S2) is underpinned by the expansion of a network of (CD45−EPCAM−CD31−) pdpn+ fibroblasts which are similar to those observed in humans and precedes lymphocyte infiltration and reverts to baseline levels upon clearance of the TLS from the tissue (Fig. 2 A and B and SI Appendix, Fig. S2). This population is characterized by expression of additional stromal cell markers, such as pdgfrα and pdgfrß, FAP, ICAM-1, VCAM-1, MadCAM, and RANK-L (Fig. 2C and SI Appendix, Fig. S2). Pdpn+ fibroblasts were found to express CXCL13, CCL19, BAFF, IL7, and LTβR (Fig. 2D and SI Appendix, Fig. S2). Interestingly, subdividing the pdpn+ population into ICAM-1+/VCAM-1+ or ICAM-1+VCAM-1− and ICAM-1−/VCAM-1+ unveiled increased expression of lymphoid chemokines, but not survival factors in the ICAM-1+/VCAM-1+ (double positive) pdpn+ fibroblasts (Fig. 2E). Fig. 2. Salivary gland inflammation induces activation and expansion of pdpn+ fibroblasts in murine salivary glands. (A) Representative flow cytometry plot of pdpn+ cells within CD45−EpCAM− cells and time course analysis of percentage of pdpn+ fibroblasts in wt mice. Data are presented as mean ± SD of 3 independent experiments with at least four biological replicates. *P < 0.05; **P < 0.01; one-way ANOVA. (B) Immunofluorescence staining for EpCAM (gray), CD4 (red), and pdpn (green) in salivary glands at days 0 and 5 p.c. (Scale bars: 100 µm.) (C) Representative viSNE plots of CD45− EpCAM−CD31− cells from salivary glands at days 0 and 5 p.c., analyzed by multicolor flow cytometry. Colors indicate cell expression level of labeled markers (pdpn, FAP, PDGFRα, PDGFRβ, ICAM-1, and VCAM-1). (D) Gene expression analysis for cxcl13, baff, ccl19, and il7 transcripts on sorted populations (pdpn+ fibroblasts, pdpn− fibroblasts, and EpCAM+ cells). Relative quantitation (RQ) was calculated with calibrator day 0 (CD45−EpCAM−CD31−pdpn− cells). Data are expressed as mean ± SD (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA. (E) Gene expression analysis for cxcl13, ccl19, and baff transcripts on fibroblast subsets sorted on differential ICAM-1 and VCAM-1 expression. Relative quantitation (RQ) was calculated with calibrator as day 0 (CD45−EpCAM−CD31−ICAM-1−VCAM-1− cells). Data are expressed as mean ± SD (n = 6). *P < 0.05; ***P < 0.001; one-way ANOVA. All together, these data demonstrate that the expression of pdpn identifies within both human and murine TLS a heterogeneous population of immunofibroblasts that are able to support the key immunological functions of survival and migration/organization exerted in the SLOs by FRCs (SI Appendix, Fig. S2). As demonstrated in human TLS fibroblasts, pdpn+ fibroblasts are characterized by the expression of IL4R, IL13R, and, as previously described, of IL22R (12), alongside TNFR and LTβR (SI Appendix, Fig. S2) (12). IL4R Engagement Regulates Stromal Cell Priming in an Animal Model of TLS Assembly. To dissect in vivo the role of these receptors in TLS assembly, we induced salivary gland inflammation in mice deficient for IL4R, IL4, and IL13. We demonstrated that, in vivo, the deficiency of IL4R or IL13, but not of IL4, resulted in a failure to up-regulate pdpn+ and to prime resident progenitors (Fig. 3A and SI Appendix, Fig. S3). Interestingly, this defect was not accompanied by defective stromal cell proliferation (SI Appendix, Fig. S3). Instead, IL4R−/− mice displayed defective TLS assembly, including decreased production of homeostatic chemokines (Fig. 3B) and formation of smaller inflammatory foci in the salivary glands (Fig. 3C). While chemokine expression was compensated in the absence of IL4R signaling by day 15 postinfection, autoantibody production was, in the IL4R−/−, completely abolished (SI Appendix, Fig. S3). Fig. 3. The IL13 pathway is significantly involved in immunofibroblast activation. (A) Flow cytometry data of the percentage of pdpn+ stroma from wt (black squares, n = 3 to 6), IL4R−/− (open squares, n = 3 to 6), IL4−/− (open circles, n = 3 to 5) and IL13−/− (black triangle, n = 3 to 5) mice at days 0, 2, and 5 p.c. **P < 0.01; ***P < 0.001; one-way ANOVA. Data are represented as mean ± SD. (B) Immunofluorescence of lymphoid aggregates in salivary glands (day 15 p.c.) from wt and IL4R−/− mice (CD3, red; CD19, blue; CXCL13 or CCL21, green). (Scale bars: 100 µm.) (C) il13 and il4 transcripts time course analysis by qRT-PCR in wt mice. Data are represented as mean ± SD of 2 to 3 independent experiments with 2 to 3 mice per group. *P < 0.05; **P < 0.01; one-way ANOVA. (D) Immunofluorescence staining for IL13 (green) and CD45 (red) at 3 h and day 2 p.c. (Scale bars: 50 µm; Inset shows higher magnification, scale bars: 10 µm.) (E) Identification of IL13+ cells in the CD45+ compartment by flow cytometry at 3 h and days 2 and 5 p.c. (F) Analysis of IL13 transcript and protein expression by fibroblasts (n = 3) and epithelial cells (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; t test. Data are represented as mean ± SD. To understand the relevance of IL13 in wild type (wt) animals, we investigated the expression of this cytokine upon salivary glands following viral infection in C57/bl6 mice. A rapid induction of IL13, but not of IL4, was observed in these animals in the early phases of TLS formation (Fig. 3C). IL13+ cells were localized in the inner part of the developing TLS in C57/bl6 mice reconstituted with IL13gfp bone marrow (Fig. 3D). Innate lymphoid cells were identified as an early source of IL13 (Fig. 3E), alongside fibroblasts and epithelial cells (Fig. 3F and SI Appendix, Fig. S3). This was confirmed by mixed bone marrow chimera experiments that demonstrate the conserved ability of mice reconstituted with IL13gfp bone marrow (deficient for IL13 in the hematopoietic compartment) to prime resident fibroblasts (SI Appendix, Fig. S3). Together, these data confirm that priming of the resident progenitors occurs independently of lymphocyte infiltration in the TLS and that IL13, but not IL4, is responsible for the early engagement of the IL4R signaling on the immunofibroblast progenitors. To test this hypothesis, we delivered recombinant IL13 (rIL13) into murine salivary glands in vivo, and we found that IL13 alone was able to induce up-regulation of pdpn, ICAM-1, and VCAM-1 (SI Appendix, Fig. S3). Immunofibroblast Proliferation Is Dependent on IL22/IL22R Interaction. Observations in wt mice demonstrated that the pdpn+ fibroblasts undergo a phase of active proliferation after priming (SI Appendix, Fig. S4); however, this is not regulated by IL13 or IL4. We therefore aimed to investigate the molecular mechanism underpinning this phenomenon. We previously demonstrated that IL22 regulates CXCL13 expression in TLS (12). Moreover, human fibroblasts isolated from pSS salivary glands expand in vitro in response to IL22, suggesting the possibility that this cytokine also mediates fibroblast proliferation in vivo, during TLS assembly. Murine fibroblasts express IL22Rα, and this expression increases significantly in pdpn+ cells upon viral infection (Fig. 4 A and B). To test the proliferative ability of IL22, we administered recombinant murine (m) IL22 to unmanipulated salivary glands in vivo and also in vitro to isolated pdpn+ fibroblasts. We observed that IL22 was sufficient to induce proliferation of pdpn+ cells both when administered in vivo (Fig. 4C) and in vitro (Fig. 4D). Correspondingly, both IL22- and IL22R-deficient mice presented a numeric defect in pdpn+ stromal cells that was significant from day 5 postinfection (Fig. 4E). This defect was accompanied by a significant decrease in BrdU incorporation by the fibroblasts (Fig. 4F) and could be reproduced by administering therapeutic doses of the anti-IL22 antibody to virus-cannulated wt mice (Fig. 4G). Together, these data suggest that, during TLS assembly, while IL13 mediates the early acquisition of an “activated phenotype” of the resident progenitors, IL22 is responsible for the expansion of this immunofibroblast network. Fig. 4. Expansion of immunofibroblasts is dependent on the IL22/IL22Rα pathway. (A) Representative plot of IL22Rα expression by CD45−EpCAM−CD31− cells at days 0 and 5 p.c. (B) Fold change of IL22Rα expression by pdpn+ (n = 3) and pdpn− (n = 3) fibroblasts, analyzed by flow cytometry. *P < 0.05; paired t test. (C) Flow cytometry analysis of Ki67+pdpn+ fibroblasts in wt salivary glands cannulated with IL22 (black bars), BSA (white bars), or PBS (gray bars) and analyzed at day 2 p.c. Data are represented as mean ± SD of 3 independent experiments, 2 mice per group. **P < 0.01; ***P < 0.001; one-way ANOVA. (D) Percentage of BrdU incorporation in pdpn+ fibroblasts isolated from wt salivary glands at day 2 p.c. and then stimulated in vitro with IL22 (black bars); with IL22, TNFα, and LTβR agonist (dark gray bars); with TNFα and LTβR agonist (light gray bars); or with PBS (white bars). Data are represented as mean ± SD of 2 independent experiments, *P < 0.05; ***P < 0.001; one-way ANOVA. (E) Percentage of pdpn+ fibroblasts in IL22Rα−/− (open circles, n = 4 to 6), IL22−/− (gray triangles, n = 4 to 6), and wt mice (black squares, n = 3 to 6). *P < 0.05; **P < 0.01; one-way ANOVA. Data are represented as mean ± SD. (F) Analysis of BrdU incorporation by pdpn+ fibroblast from wt (black bars, n = 4 to 6) and IL22Rα−/− (white bars, n = 3 to 5) mice (days 2, 5, 8, 15, and 23 p.c.). *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA. Data are represented as mean ± SD. (G) Analysis of BrdU+ pdpn+ fibroblasts at days 5 and 8 p.c. with anti-IL22 (open bars), control Ig (gray bars), or untreated (black bars). Data are presented as the mean ± SD of 2 independent experiments, with 2 to 3 mice per group. **P < 0.01; one-way ANOVA. Priming and Expansion of pdpn+ Fibroblasts in TLS Are Independent of LTα1β2 and RORγ+ Cells. Full development of FRCs in SLOs is largely regulated by LTα1β2, provided during embryogenesis by RORγ+ lymphoid tissue inducer cells21. To investigate the effects that LTα1β2 and RORγ exert on the identified population of immunofibroblasts, we induced salivary gland inflammation in Ltßr−/− and Rorγ−/− mice. Both strains exhibited normal up-regulation of ICAM-1, VCAM-1, and pdpn and normal proliferation of the pdpn+ fibroblasts up to day 8 p.c. (Fig. 5A and SI Appendix, Fig. S5). Interestingly, by day 15 p.c., both strains exhibited a defect in the number and proliferation of pdpn+ fibroblasts, together with a reduction in the percentage of the ICAM-1/VCAM-1 intermediate and high cells (Fig. 5A and SI Appendix, Fig. S5). Fig. 5. LTα1β2 and RORγ+ cells regulate chemokine expression but not early fibroblast priming or expansion. (A) Time course flow cytometry analysis of the percentage of pdpn+ fibroblasts from wt (black squares, n = 3 to 5), Rorγ−/− (open squares, n = 3 to 5), and Ltßr−/− (gray squares, n = 3 to 5) mice. *P < 0.05; one-way ANOVA. Data are represented as mean ± SD. (B and C) Analysis of cxcl13 and ccl19 mRNA transcripts by qRT-PCR in wt (black bars, n = 7 to 12), Rorγ−/− (open bars, n = 4 to 5), and Ltßr−/− (gray bars, n = 4 to 7) mice at days 5, 8, 15, and 23 p.c. *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA. Data are represented as mean ± SD. (D and E) Immunofluorescence of salivary glands (day 15 p.c.) from wt, Ltßr−/−, and Rorγ−/− mice [CD3, red; CD19, blue; CXCL13 (D) or CCL21 (E), green]. (Scale bars: 100 µm.) (F) qRT-PCR analysis of cxcl13 and ccl19 mRNA from wt (black bars, n = 4 to 6) and Rag2−/− (white bars, n = 4 to 6) salivary glands at days 5, 8, 15, and 23 p.c. *P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA. Data are represented as mean ± SD. (G) Time course flow cytometry analysis of the percentage of pdpn+ fibroblasts from wt (black squares, n = 4 to 6) and Rag2−/− (open squares, n = 4 to 6) mice. *P < 0.05; **P < 0.01; one-way ANOVA. Data are represented as mean ± SD. During TLS assembly, Ltßr−/− and Rorγ−/− mice failed to express normal levels of lymphoid chemokines and to form organized foci upon viral infection (Fig. 5 B–E). These data suggest that, while not required for priming and expansion of the fibroblastic network, Ltα1β2- and Rorγ-positive cells play a nonredundant role at the final differentiation and stabilization of the functional phenotype of the immunofibroblasts. Lymphocytes Are Dispensable for pdpn+ Fibroblast Priming but Required for Expansion and Conversion of the Stromal Network to a Fully Mature Immune Phenotype. The data generated suggested that different phases of fibroblast modifications during TLS assembly are regulated by diverse cytokines and depend on the interaction between fibroblasts and different cell types. To better understand this phenomenon, we induced TLS formation in lymphocyte-deficient mice. As expected, Rag2−/− mice infected with adenovirus failed to induce homeostatic chemokine expression and exhibited a phenotype similar to that of LtβR−/− mice (Fig. 5F). However, the analysis of the fibroblast compartment in Rag2−/− mice showed an early significant defect in the expansion of the pdpn+ fibroblasts, not observed in the absence of the LTβR signal. This defect was significant from day 5 post viral infection (Fig. 5G) and closely mimicked the phenotype observed in the IL22R−/− and IL22−/− mice (Fig. 4). Interestingly, the early fibroblast priming was maintained in Rag2−/− (Fig. 5G), confirming that IL13 expression and the engagement of IL4R in the salivary gland at this stage is not dependent on lymphocytes. Accordingly, PCR analysis for IL13 in the Rag2−/− demonstrated a conserved signal for this cytokine (SI Appendix, Fig. S5). Deletion of pdpn+/Fap+ Fibroblasts Abrogates TLS Establishment and Compromises Establishment of Local Pathology. To finally demonstrate whether the fibroblast network that we described is required for TLS assembly and maintenance in vivo, we utilized the Dm2 mouse to deplete pdpn-expressing cells. Dm2 mice have been previously used to delete pdpn+ FRCs in SLOs, taking advantage of the expression of FAP+ on pdpn+ FRCs and the engineered expression of the diphtheria receptor (DTR) under the FAP promoter (5, 24, 25). We firstly demonstrated that, similarly to SLOs, pdpn+ cells in the TLS forming in both wt mice and Dm2 salivary glands express FAP (Fig. 6 A and B) and that FAP expression is up-regulated upon inflammation in viral-infected salivary glands (Fig. 6 C and D). We then treated Dm2 mice with diptheria toxin as previously described (5, 24, 25) before the induction of TLS (Materials and Methods). By day 8 postinfection in Dm2+, but not in control treated mice, there was a significant loss of pdpn+ stromal cells in the salivary gland (Fig. 6E and SI Appendix, Fig. S6); this effect was associated with a reduced number of lymphocytes (Fig. 6F and SI Appendix, Fig. S5), less organized TLS (Fig. 6G and SI Appendix, Fig. S6), and low chemokine expression in infected glands (Fig. 6H). Local disaggregation of TLS resulted in abrogated autoantibody production (Fig. 6I). Given the potential interference of FAP systemic deletion on the immune response (5), we performed local deletion of FAP+ cells by delivering DTX directly in the salivary glands. Infected mice treated with local DTX also display loss of pdpn+ fibroblasts and a decrease in CD45+ cells, activated T cells, and B cells (SI Appendix, Fig. S6). Overall, local stromal cell depletion was less efficient than systemic and was reflected in the lack of impact on ANA production in treated mice. Fig. 6. Depletion of FAP+ fibroblasts impairs the formation of TLS. (A) Immunofluorescence staining of FAP (red) and DAPI (gray) in wt salivary glands at days 0 and 15 p.c. (Scale bars: 200 µm.) (B) Representative flow cytometry plot of FAP expression by pdpn+ fibroblasts. The gate shows percentage of FAP+ pdpn+ cells. (C) Time course analysis of the percentage of pdpn+ FAP+ fibroblasts in wt mice. Data are presented as mean ± SD. (D) Analysis of fap mRNA transcript by qRT-PCR in wt salivary glands at days 0, 2, 5, and 15 p.c. (n = 4 to 9). *P < 0.05; ***P < 0.001; one-way ANOVA. Data are represented as mean ± SD. (E) Flow cytometry data for absolute numbers of pdpn+ fibroblasts at day 8 p.c. in Lm DTX treated (black bars, n = 8) and Dm2 DTX treated (red bars, n = 6). ***P < 0.001; t test. Data are represented as mean ± SD. (F) Flow cytometry data for absolute numbers of T and B lymphocytes at days 8, 15, and 23 p.c. in Lm DTX treated (black squares) and Dm2 DTX treated (red bars). Data are represented as mean ± SD of 2 independent experiments with at least 3 mice for each experiment. **P < 0.01; one-way ANOVA. (G) Immunofluorescence staining of CD3 (red) and CD19 (blue) in Lm DTX treated and Dm2 DTX treated at day 8 p.c. (Scale bars: 100 μm.) (H) qRT-PCR analysis of cxcl13 and ccl19 mRNA from Lm DTX treated (black bars, n = 6) and Dm2 DTX treated (red bars, n = 4) salivary glands at day 8 p.c. Data are represented as mean ± SD. (I) Percentage of positive mice for ANA in lm DTX treated (black bar) and Dm2 DTX treated (red bar) experimental groups at day 23 p.c. Discussion TLS form in response to the immunological requirement to generate a local immune response against invading pathogens and local antigens (26). However, TLS persistence in autoimmune conditions correlates with worse outcome, including the development of MALT (mucosal-associated lymphoid tissue) lymphoma and increased systemic manifestations (1). Resistance to immune-cell depletion in subsets of patients with TLS-associated autoimmune conditions has been linked to the inability to interfere with local excess of survival factors and cytokines produced within the TLS. This suggests that the identification of the molecular mechanisms responsible for the establishment and maintenance of this local microenvironment could be exploited therapeutically (2). Here, we demonstrate that TLS assembly, both in humans and in an animal model of TLS, is underpinned by the formation of a network of pdpn+ immunofibroblasts, phenotypically and functionally similar to the FRC networks described within SLOs. Interestingly, murine and human fibroblasts display differential associations between expression of chemokines and survival factors and expression of ICAM-1, VCAM-1, and CD34. The developmental imprinting underpinning these differences is currently under investigation. The cellular requirements and microenvironmental signals responsible for the formation of this fibroblast network, both in humans and mice, appear to be conserved across species and unique to TLS and encompass the engagement of Th2 cytokines and IL22, in synergy with LTα1β2. The analysis of this cascade and the cellular interaction responsible for it demonstrates that lymphocytes are dispensable for the early priming of the immunofibroblast progenitors in TLS. Lymphocytes are, however, required for the expansion of the network and for its full conversion to an immune phenotype. Genome-wide association studies have previously identified MHC class II haplotypes and components of the IL4/IL13 receptor complex, including Tyk2, as independent risk factors in immune-mediated inflammatory diseases (27, 28). This risk was classically associated with the role of the IL4R pathway in CD4 T cell function. However, MHC class II, the IL4/IL13 receptor complex, and Tyk2 expression are expressed and functional in nonhematopoietic cells, including smooth muscle cells. Moreover, IL4R activation is known to regulate adult muscle regeneration (29). Previous reports have suggested the association between IL13 and the production of autoantibodies (17⇓⇓⇓⇓–22). Nevertheless, no functional proof of this relationship has been provided outside the role of this pathway in B and T cell regulation (30). Here, we demonstrate that the release of IL13 by resident ILCs and stromal cells, including fibroblasts and epithelium, directly regulates phenotypical changes but not proliferation of a population of pdpn+ immunofibroblast progenitors. This IL4R-mediated priming is required for the up-regulation of adhesion molecules, in particular VCAM-1, that enable the interaction of the fibroblasts with incoming leukocytes. IL13 production by resident stromal cells strongly assimilates this intrinsic and rapid response with the mechanisms of immunosurveillance ascribed to this cytokine in carcinogenesis (31). In this latter model, IL13 regulated the release of thymic stromal lymphopoietin and IL33, thereby accelerating epithelium repair (31). In our example, IL13 acts on a resident population of fibroblasts, modulating their ability to interact with incoming immune cells and form TLS. Together, these observations provide evidence in support of a critical role of IL13 in response to external danger signals in a series of pathogenic settings that extend from inflammation to autoimmunity and cancer. Intriguingly, IL4R engagement was not able to induce fibroblast proliferation. FRC expansion postimmunization has been described in SLOs and deemed dependent on LTα1β2 and IL4R (32⇓–34). Here, we demonstrate that, in TLS, expansion of pdpn+ fibroblasts also occurs, with active stromal cell proliferation peaking at day 5 postinfection. However, this phenomenon is largely independent of LTα1β2 and RORγt+ cells, but regulated by lymphocytes and IL22, a cytokine known to promote stromal cell repair and proliferation (35⇓⇓–38). The biological effect described here in murine and human fibroblasts, together with our previous report on the link between IL22 and CXCL13 expression in TLS, strongly advocates for an intervention against this cytokine in clinical practice. Interestingly, RORγt-dependent IL17 production appears not to play a major role in this system as a fairly conserved expansion of the immunofibroblasts occurs, along with TLS formation in RORγt−/− mice. Whether this is a feature specific of the TLS forming at mucosal sites is not clear as IL17 production has been deemed important for TLS establishment in other organs (13⇓–15). We previously demonstrated that interfering in vivo with IL22 expression by the use of a blocking antibody profoundly affects TLS maintenance in the tissue (12). Here, we expanded this observation and reported the formation of aberrant TLS with decreased immunofibroblast proliferation in mice treated with anti-IL22 antibodies, but also in mice deficient for IL4R and in a model of fibroblast depletion in vivo (Dm2). Previous work demonstrated that stromal cell depletion in SLOs of Dm2 mice only marginally affects lymphoid organ architecture (5). However, the impact on immune effector functions of Dm2 mice with diphtheria toxin demonstrates that systemic depletion of immunofibroblasts in TLS exerts a more profound effect, severely compromising aggregate assembly, inducing loss of anatomical organization, diminishing lymphocyte recruitment, and resolution of tissue pathology. Importantly, in this model and, similarly, in the absence of the IL4R or IL22R signaling, a reduction in the production of antinuclear antibodies was observed. These observations highlight the importance of a normal fibroblast network to support autoantibody production. Stromal cell depletion, induced by local DTX delivery, was less efficient in depleting immunofibroblasts. However, it still profoundly affected local pathology, but not systemic ANA production in viral infected animals. Several reports have highlighted the association between failure to respond to B cell-depleting therapies and the persistence of TLS in the tissue of patients with autoimmune conditions (39⇓⇓⇓⇓⇓⇓⇓–47). These observations establish a pathogenic role for TLS and their local microenvironment to sustain pathology. Here, we have demonstrated that the formation of a network of immune fibroblasts in TLS is responsible for the establishment of the TLS pathogenic microenvironment and that interfering with the signals responsible for its establishment profoundly affects local pathology and interferes with autoantibody production, providing a strong rationale for targeting immunofibroblasts in the treatment of TLS-associated diseases. Materials and Methods Study Design. Immunohistochemistry, immunofluorescence (IF), and flow cytometry were used to define the phenotype of immunofibroblasts in the salivary glands of patients with pSS. Tissue was obtained from patients recruited in the OASIS cohort (Optimising assessments in Sjögren’s syndrome) at University of Birmingham under ethics no. 10-018. IL13, IL4, and IL22 receptor expression was detected in both humans and mice, and differential biological effects were observed in fibroblasts stimulated with these molecules. To dissect these effects in vivo, we studied the dynamic response of a population of pdpn+ cells in a model of TLS assembly in wt mice and in mutants defective for IL13, IL4R, IL4, IL22, IL22R, LTβR, and Rorγ, as well as Rag2 mice. Mice were maintained in the Biomedical Service Unit at the University of Birmingham according to Home Office and local ethics committee regulations (University of Birmingham), under license no. P4B291FAA. IF, flow cytometry, and qRT PCR were used to assess differential effects in these mutants in the salivary glands of mice killed at different time points. Recombinant proteins for the molecules of interest and a blocking antibody against IL22 were used in gain- or loss-of-function experiments to dissect the requirements of these pathways in fibroblast maturation and TLS formation. Finally, to prove the effect that pdpn+ fibroblast deletion would exert on TLS, we used DM2 mice that express the diphtheria toxin receptor under the FAP promoter. Detailed materials and methods can be found in SI Appendix. Acknowledgments We thank Peter Lane, David Withers, Jorge Caamano, Andrew McKenzie, Adam Cunningham, Klaus Pfeffer, and Haley Daniels for providing animals; and Technology Hub (University of Birmingham) for flow cytometry, imaging, and PCR. We are indebted to the Biomedical Services Unit and Biological Services Facility for maintaining the colonies. F.B. was funded by the Wellcome Trust and is now an Arthritis Research UK (ARUK) Senior Fellow. This work was supported by ARUK Grant G0601156 (to C.D.B. and M.C.C.); National Centre for the Replacement, Refinement, and Reduction of Animals in Research, Grant NC/K000527/1 and Human Frontier Science Program Grant RGP0006/2009 (to M.C.C.); and grants from the Ligue Nationale Contre le Cancer (to K.T.). B.A.F. and S.J.B. have received support from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant BRC-1215-20009). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Footnotes ↵1S.N. and J.C. contributed equally to this work. ↵2Present address: Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7FY, United Kingdom. ↵3To whom correspondence may be addressed. Email: f.barone{at}bham.ac.uk or mark.coles{at}kennedy.ox.ac.uk. Author contributions: S.N., K.T., S.A.L., B.A.F., C.D.B., M.C.C., and F.B. designed research; S.N., J.C., C.G.S., V.I., D.H.G., F.M., D.R., J.T., M.S., S.A., B.G., S.J.B., A.F., and K.T. performed research; D.T.F. contributed new reagents/analytic tools; S.N., J.C., and F.B. analyzed data; and S.N. and F.B. wrote the paper. The authors declare no conflict of interest. This article is a PNAS Direct Submission. This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1905301116/-/DCSupplemental. Copyright © 2019 the Author(s). Published by PNAS. This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND). References ↵ C. Pitzalis, G. W. Jones, M. Bombardieri, S. A. Jones, Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447–462 (2014).OpenUrlCrossRefPubMed ↵ F. Barone et al., Stromal fibroblasts in tertiary lymphoid structures: A novel target in chronic inflammation. Front. Immunol. 7, 477 (2016).OpenUrl ↵ C. D. Buckley, F. Barone, S. Nayar, C. Bénézech, J. Caamaño, Stromal cells in chronic inflammation and tertiary lymphoid organ formation. Annu. Rev. Immunol. 33, 715–745 (2015).OpenUrlCrossRefPubMed ↵ L. B. Rodda et al., Single-cell RNA sequencing of lymph node stromal cells reveals niche-associated heterogeneity. Immunity 48, 1014–1028.e6 (2018).OpenUrl ↵ A. E. Denton, E. W. Roberts, M. A. Linterman, D. T. Fearon, Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 111, 12139–12144 (2014). ↵ M. Novkovic, L. Onder, G. Bocharov, B. Ludewig, Graph theory-based analysis of the lymph node fibroblastic reticular cell network. Methods Mol. Biol. 1591, 43–57 (2017).OpenUrl ↵ M. Novkovic et al., Topological small-world organization of the fibroblastic reticular cell network determines lymph node functionality. PLoS Biol. 14, e1002515 (2016).OpenUrlCrossRefPubMed ↵ C. Bénézech et al., Ontogeny of stromal organizer cells during lymph node development. J. Immunol. 184, 4521–4530 (2010). ↵ T. Cupedo, G. Kraal, R. E. Mebius, The role of CD45+CD4+CD3- cells in lymphoid organ development. Immunol. Rev. 189, 41–50 (2002).OpenUrlCrossRefPubMed ↵ G. Eberl, D. R. Littman, The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer’s patches. Immunol. Rev. 195, 81–90 (2003).OpenUrlCrossRefPubMed ↵ L. Peduto et al., Inflammation recapitulates the ontogeny of lymphoid stromal cells. J. Immunol. 182, 5789–5799 (2009). ↵ F. Barone et al., IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl. Acad. Sci. U.S.A. 112, 11024–11029 (2015). ↵ A. Peters et al., Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986–996 (2011).OpenUrlCrossRefPubMed ↵ N. B. Pikor et al., Integration of Th17- and lymphotoxin-derived signals initiates meningeal-resident stromal cell remodeling to propagate neuroinflammation. Immunity 43, 1160–1173 (2015).OpenUrlCrossRefPubMed ↵ J. Rangel-Moreno et al., The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12, 639–646 (2011).OpenUrlCrossRefPubMed ↵ A. Link et al., Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am. J. Pathol. 178, 1662–1675 (2011).OpenUrlCrossRefPubMed ↵ A. Spadaro, T. Rinaldi, V. Riccieri, E. Taccari, G. Valesini, Interleukin-13 in autoimmune rheumatic diseases: Relationship with the autoantibody profile. Clin. Exp. Rheumatol. 20, 213–216 (2002).OpenUrlPubMed ↵ J. Mahlios, Y. Zhuang, Contribution of IL-13 to early exocrinopathy in Id3-/- mice. Mol. Immunol. 49, 227–233 (2011).OpenUrlPubMed ↵ Z. Xu, Y. Chen, Determination of serum interleukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25, 360–361 (2005).OpenUrlCrossRefPubMed ↵ G. M. Villarreal, J. Alcocer-Varela, L. Llorente, Differential interleukin (IL)-10 and IL-13 gene expression in vivo in salivary glands and peripheral blood mononuclear cells from patients with primary Sjögren’s syndrome. Immunol. Lett. 49, 105–109 (1996).OpenUrlCrossRefPubMed ↵ D. I. Mitsias et al., The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren’s syndrome. Clin. Exp. Immunol. 128, 562–568 (2002).OpenUrlCrossRefPubMed ↵ K. Raza et al., Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 7, R784–R795 (2005).OpenUrlCrossRefPubMed ↵ M. Bombardieri et al., Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J. Immunol. 189, 3767–3776 (2012). ↵ D. T. Fearon, The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2, 187–193 (2014). ↵ M. Kraman et al., Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827–830 (2010). ↵ G. W. Jones, S. A. Jones, Ectopic lymphoid follicles: Inducible centres for generating antigen-specific immune responses within tissues. Immunology 147, 141–151 (2016).OpenUrlCrossRef ↵Wellcome Trust Case-Control Consortium (WTCCC) M. Ban et al.; Wellcome Trust Case-Control Consortium (WTCCC), Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur. J. Hum. Genet. 17, 1309–1313 (2009).OpenUrlCrossRefPubMed ↵ P. D. Burbelo, K. Ambatipudi, I. Alevizos, Genome-wide association studies in Sjögren’s syndrome: What do the genes tell us about disease pathogenesis? Autoimmun. Rev. 13, 756–761 (2014).OpenUrlCrossRefPubMed ↵ J. E. Heredia et al., Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 153, 376–388 (2013).OpenUrlCrossRefPubMed ↵ T. A. Wynn, IL-13 effector functions. Annu. Rev. Immunol. 21, 425–456 (2003).OpenUrlCrossRefPubMed ↵ T. Dalessandri, G. Crawford, M. Hayes, R. Castro Seoane, J. Strid, IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. Nat. Commun. 7, 12080 (2016).OpenUrl ↵ C. Y. Yang et al., Trapping of naive lymphocytes triggers rapid growth and remodeling of the fibroblast network in reactive murine lymph nodes. Proc. Natl. Acad. Sci. U.S.A. 111, E109–E118 (2014). ↵ L. K. Dubey et al., Lymphotoxin-dependent B cell-FRC crosstalk promotes de novo follicle formation and antibody production following intestinal helminth infection. Cell Rep. 15, 1527–1541 (2016).OpenUrl ↵ L. K. Dubey, P. Karempudi, S. A. Luther, B. Ludewig, N. L. Harris, Interactions between fibroblastic reticular cells and B cells promote mesenteric lymph node lymphangiogenesis. Nat. Commun. 8, 367 (2017).OpenUrlCrossRef ↵ S. Pantelyushin et al., Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122, 2252–2256 (2012).OpenUrlCrossRefPubMed ↵ A. Andoh et al., Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129, 969–984 (2005).OpenUrlCrossRefPubMed ↵ M. Colonna, Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31, 15–23 (2009).OpenUrlCrossRefPubMed ↵ J. A. Dudakov, A. M. Hanash, M. R. van den Brink, Interleukin-22: Immunobiology and pathology. Annu. Rev. Immunol. 33, 747–785 (2015).OpenUrlCrossRefPubMed ↵ F. Barone, S. Colafrancesco, Sjögren’s syndrome: From pathogenesis to novel therapeutic targets. Clin. Exp. Rheumatol. 34 (suppl. 98), 58–62 (2016).OpenUrl ↵ F. Lavie et al., Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: Insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66, 700–703 (2007). ↵ S. De Vita et al., Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: Evidence for long-term efficacy. Clin. Exp. Rheumatol. 32, 490–494 (2014).OpenUrlPubMed ↵ L. Quartuccio et al., Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation. Int. J. Rheumatol. 2009, 424935 (2009).OpenUrlPubMed ↵ L. Quartuccio et al., Resistance to rituximab therapy and local BAFF overexpression in Sjögren’s syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol. J. 2, 38–43 (2008).OpenUrlCrossRefPubMed ↵ B. Marston, A. Palanichamy, J. H. Anolik, B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 22, 307–315 (2010).OpenUrlCrossRefPubMed ↵ S. Bugatti, B. Vitolo, R. Caporali, C. Montecucco, A. Manzo, B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers. BioMed Res. Int. 2014, 681678 (2014).OpenUrl ↵ C. Gorman, M. Leandro, D. Isenberg, B cell depletion in autoimmune disease. Arthritis Res. Ther. 5 (suppl. 4), S17–S21 (2003).OpenUrlCrossRefPubMed ↵ G. Nocturne, X. Mariette, B cells in the pathogenesis of primary Sjögren syndrome. Nat. Rev. Rheumatol. 14, 133–145 (2018).OpenUrl
No comment yet.
Scooped by Gilbert C FAURE
June 24, 2019 1:31 PM
Scoop.it!

IL-6: linking chronic inflammation and vascular calcification

IL-6: linking chronic inflammation and vascular calcification | Immunology | Scoop.it
New data highlight the contribution of IL-6 to vascular calcification in chronic inflammation. Given that increased vascular calcification and accelerated atherosclerosis occur in patients with chronic inflammatory diseases, new therapies that block the IL-6 pathway might reduce the risk of cardiovascular events in these patients.
No comment yet.
Scooped by Gilbert C FAURE
June 24, 2019 10:53 AM
Scoop.it!

Unmasking senescence: context-dependent effects of SASP in cancer | Nature Reviews Cancer

No comment yet.
Scooped by Gilbert C FAURE
June 23, 2019 4:06 AM
Scoop.it!

Fibroblastic reticular cells at the nexus of innate and adaptive immune responses - Perez‐Shibayama - 2019 - Immunological Reviews - Wiley Online Library

Summary Lymphoid organs guarantee productive immune cell interactions through the establishment of distinct microenvironmental niches that are built by fibroblastic reticular cells (FRC). These specialized immune‐interacting fibroblasts coordinate the migration and positioning of lymphoid and myeloid cells in lymphoid organs and provide essential survival and differentiation factors during homeostasis and immune activation. In this review, we will outline the current knowledge on FRC functions in secondary lymphoid organs such as lymph nodes, spleen and Peyer's patches and will discuss how FRCs contribute to the regulation of immune processes in fat‐associated lymphoid clusters. Moreover, recent evidence indicates that FRC critically impact immune regulatory processes, for example, through cytokine deprivation during immune activation or through fostering the induction of regulatory T cells. Finally, we highlight how different FRC subsets integrate innate immunological signals and molecular cues from immune cells to fulfill their function as nexus between innate and adaptive immune responses. 1 FIBROBLASTIC RETICULAR CELLS UNDERPIN THE STRUCTURE OF LYMPHOID ORGANS The activation of adaptive immune responses depends on the interaction of professional antigen‐presenting cells (APC) with T and B cells in specialized compartments of lymphoid organs. Secondary lymphoid organs (SLO) are strategically positioned at routes of pathogen invasion and thereby increase the likelihood of lymphocytes to encounter their cognate antigens at a particular location and during a certain time window. Lymph nodes are found at convergence points of afferent lymph vessels and surveil extracellular fluids from separate areas of peripheral tissue. Other classical SLO such as Peyer′s patches are located right below the area of the intestinal surface they surveil, while the splenic white pulp provides specialized niches for the development of immune responses against blood‐borne pathogens.1 Nonclassical SLO such as fat‐associated lymphoid clusters (FALC) serve as surveillance hubs of the body cavities by sampling the fluids that are secreted by mesothelial cells.2 Transient lymphoid aggregates that display T‐ and B‐cell zone segregation and that appear in inflamed tissues are referred to as tertiary lymphoid structures (TLS, also known as tertiary lymphoid organs).3 Fluid flow in lymphoid organs is sustained by endothelial stromal cells with blood endothelial cells facilitating the delivery of oxygen and nutrients via blood vessels and lymphatic endothelial cells granting drainage of extracellular liquids via lymphatic vessels. The structural integrity of all lymphoid organs is determined by fibroblastic stromal cells that build, for example, the capsule of lymph nodes or the spleen. In addition, specialized immune‐interacting fibroblasts, generally termed fibroblastic reticular cells (FRC), form the scaffold structures that underpin the distinct microenvironments required for efficient immune cell interactions (Figure 1). FRC crucially contribute to the functioning of the immune system through the secretion of homeostatic chemokines to coordinate the interaction between APC and lymphocytes and provide growth and survival factors that nurture both innate and adaptive lymphocytes.4, 5 Moreover, FRC are equipped with a large range of pattern recognition receptors6-8 that play a crucial role in the control innate immune reactions. The detection of pathogen‐associated molecular signatures by germline‐encoded receptors is a key determinant for the immune system to distinguish harmful molecules of foreign origin from inoccuous self‐molecules.9, 10 Sensing of microbial products by pattern recognition receptors expressed by APC such as dendritic cells and macrophages has been considered as a key step for the activation of the adaptive immune system.9, 11 However, recent studies have revealed that FRC in classical and nonclassical SLO actively shape adaptive immune responses through the integration of innate immunological signals.8, 12 In this review, we will highlight the ability of FRC to generate tissue‐specific microenvironmental niches that orchestrate complex immunological processes and discuss recent work that has revealed the role of FRC as an important nexus of innate and adaptive immune responses. 2 DIVERSITY OF FIBROBLASTIC RETICULAR CELLS IN LYMPHOID ORGANS The most commonly used distinction of endothelial and fibroblastic stromal cells of SLO relies on the expression of the endothelial marker CD31 (platelet endothelial cell adhesion molecule‐1, PECAM‐1) and the fibroblast marker podoplanin (PDPN).13 While PDPN expression captures the majority of FRC in lymph nodes, the expression of this marker in the spleen is restricted mainly to FRC in the T‐cell zone.14 Moreover, PDPN is a surface molecule that is expressed by fibroblasts in nonlymphoid tissues and in tumors15 rendering this marker unsuitable to specifically track lymphoid tissue FRC. In contrast, the promoter activity of the FRC signature genes Ccl19 and Cxcl13 is well‐suited to capture the complexity of the immune‐interacting fibroblasts in SLO.16, 17 Indeed, the Ccl19‐Cre model facilitates targeting of FRC in all relevant microenvironments in lymph nodes,16, 18, 19 in Peyer's patches12 and in the white pulp of the spleen.20 Likewise, the Cxcl13‐Cre/tdTomato transgene targets the majority of FRC in all SLO.17 The combination of such advanced transgenic mouse models with single‐cell RNA‐seq‐based analyses of lymph node7, 21 and splenic white pulp22 FRC will enable a series of novel studies to further explore the functional complexity of FRC in lymphoid organs. 2.1 The many shapes of FRC in classical secondary lymphoid organs While the differentiation trajectories of splenic white pulp FRC from perivascular progenitors have been delineated recently using Ccl19 promoter‐based cell fate mapping22 and lineage tracing,20 the origin of lymph node FRC has not yet been fully elucidated. Nevertheless, the aggregation of Ccl19‐Cre+ and Cxcl13‐Cre+ cells in the vicinity of blood vessels of the lymph node anlage16, 17 strongly suggests that lymph node FRC originate from myofibroblastic progenitors in the perivascular space. It appears that these precursor cells are able to generate the various FRC subsets that underpin the major compartments of the lymph node (Figure 1A). The lymph fluid from peripheral tissues that arrives to the lymph node via the afferent lymph vessels is drained through the subcapsular sinus which is lined by lymphatic endothelial cells and, beneath the subcapsular sinus floor, by several layers of marginal reticular cells (MRC).23 These cells can be distinguished from other FRC subsets in lymph nodes by the expression of mucosal vascular addressin cell adhesion molecule 1 (MAdCAM‐1), receptor activator of nuclear factor kappa‐Β ligand (RANKL, TNFSF11), and CXCL13.23 In the spleen, MRC support immune responsiveness by supporting the capture and delivery of antigens from the marginal zone to B‐cell follicles.24 The expression of RANKL by Ccl19‐Cre+ lymph node MRC has been shown to be critical for the integrity of lymphatic endothelial cells in the subcapsular sinus25 indicating that MRC actively participate in shaping the cellular environment of the lymph node. Likewise, splenic white pulp MRC impact the phenotype of their interacting immune cell partners. For example, Notch 2‐driven differentiation of marginal zone B cells and of Esam+ dendritic cells requires the expression of the Notch ligand Delta‐like (DL)1 in splenic Ccl19‐Cre+ cells,26 while RANK has been shown to maintain myeloid cell populations in the marginal zone to secure initiation of antiviral immune responses.27 As an extension from the MRC layer unfolds the conduit system through the lymph node parenchyma as a fibrillary network formed by FRC.28 Conduits both in lymph nodes and in the splenic white pulp are ensheathed by FRC and consist of a collagen‐rich core that is surrounded by a microfibrillar zone and a basement membrane.29, 30 The conduit system conveys low‐molecular‐weight substances such as chemokines and antigens from the lymph node subcapsular sinus through the T‐cell area toward high endothelial venules.30 A recent report revealed that IgM transiently gains access to the luminal side of the lymph node conduit system to facilitate rapid export of early‐response IgM antibodies out of the lymph node parenchyma.31 In sum, MRC of lymph nodes and the splenic white pulp shape the border region of lymphoid tissues through the dedicated interaction with immune cells and other stromal cells and by maintaining communication channels for rapid distribution of immunologically relevant information. It will be important to fully exploit existing and novel reticular cell targeting approaches (such as the CollagenVI‐Cre model32) to characterize the function of MRC in Peyer's patches. T‐cell zone reticular cells (TRC), ie, the FRC that co‐localize predominantly with T cells and dendritic cells, express PDPN and the signature chemokines CCL19 and CCL21.12-14, 22 It is important to reiterate that PDPN expression in lymph nodes can be found in almost all FRC subsets and that high PDPN expression is associated with maturation into fully immunocompetent FRC,16 while PDPN expression both in Peyer's patches and in the splenic white pulp is mainly found in TRC.12, 22 Both T cells and dendritic cells are in close contact with TRC and move along their projections within the T‐cell area.33 The mobility of dendritic cells is boosted by the ligation of the C‐type lectin‐like receptor 2 (CLEC‐2) with PDPN on TRC.34 Moreover, lymph node TRC are thought to function as the major source of the cytokine IL‐7 to promote T‐cell homeostasis.13 However, since IL‐7 can also be produced by lymphatic endothelial cells within lymph nodes35 and in the afferent lymphatics,36 the specific function of TRC‐derived IL‐7 for T‐cell sustenance and activation remains to be demonstrated. B‐cell follicles harbor distinct FRC subsets that produce CXCL13, the B cell‐attracting chemokine that binds to CXCR5.37 As mentioned above, CXCL13‐expressing MRC extend into the B cell follicle, while the most prominent reticular cell subset that underpins the B‐cell area has been named follicular dendritic cell (FDC).38 Due to their dendritic morphology, FDC have been assumed to be related to conventional dendritic cells, ie, to originate from bone marrow progenitors. Only recently, the progenitor cell of FDC has been revealed as perivascular myofibroblast that is characterized by the expression of platelet‐derived growth factor receptor β (Pdgfrb, CD140b).39 FDC in the B cell follicle can be identified by the expression the complement receptors CD21 and CD35 and can be found both in primary and secondary follicles.40 The main functions of FDC are the retention and presentation of particulate antigen on their surface to B cells using a broad range of FCγ‐receptors (ie, CD16, CD32)41 and the promotion of affinity maturation and somatic hypermutation of B cells in the germinal center reaction.42 FDC and probably other FRC subsets43 in the B‐cell follicle control the survival of B cells via B cell activation factor (BAFF) or transmembrane activator and CAML interactor (TACI).44 It has been suggested that the dark zone of the germinal center harbors a subset of CXCL12‐expressing reticular cells (CRC) that express PDPN and can be lineage‐traced using the Ccl19‐Cre and CD21‐Cre model.18 However, a unique phenotype of CRC could not be revealed using single‐cell RNA‐seq analysis7 indicating that the phenotypical distinction of FRC/FDC subsets underpinning the germinal center is still unclear. A main fraction of FRC express markers that are indicative for their perivascular location such as Itga7 (integrin α7), Pdgfrb (CD140b), and Acta2 (αSMA) in lymph nodes6, 7 and Ly6a (Sca‐1), Pdgfra (CD140a), and Vcam1 (CD106) in the spleen.22 It is likely that the perivascular reticular cell (PRC) fraction harbors the adult progenitor of all FRC subsets.22, 39 Other regions of the lymph node such as the deep cortical area appear to harbor a subset of FRC that is characterized by the expression of CCL21a, CXCL12, and LepR.19 This area of the lymph node is occupied by T cells, dendritic cells, and B cells suggesting that FRC acquire distinct phenotypical properties when they interact with multiple cell types. Indeed, FRC attain yet other properties when they co‐localize in medullary cords with macrophages, NK cells, and plasma cells.19 In this location, medullary reticular cells (medRC) express high levels of CXCL12, IL‐6, and BAFF and facilitate thereby the formation of dedicated niches for plasma cells.45 Single‐cell RNA‐seq analysis has confirmed the existence of at least two FRC subsets that localize in the medullary region indicating that medRC also promote the maintenance of NK cells in this region.7 Clearly, further studies are required to unveil the molecular properties and function of FRC subsets not only in the lymph node B‐cell niches but also in the different microenvironments of classical SLO. 2.2 Limited FRC heterogeneity in nonclassical SLO and TLS While the formation of classical SLO, ie, lymph nodes, splenic white pulp and Peyer's patches, is fully dependent on the presence of the lymphotoxin‐β receptor,46 the generation of nonclassical SLO (eg, FALC) or TLS (eg, inducible bronchus‐associated lymphoid tissue [BALT]) is largely independent of this pathway.2 For example, the formation of FALC requires the activation of stromal cells via the production of inflammatory cytokines such as the tumor necrosis factor (TNF), which are induced through the presence of microbiota in the intestine.47 Interestingly, the highly activated milieu of the intestinal lamina propria does not provide sufficient cytokine‐mediated stimulation to override the dependence of cryptopatch and isolated follicle formation on lymphotoxin‐β receptor signaling,48 indicating that the pathways employed in the generation of nonclassical SLOs are organ‐dependent. Likewise, TLS, which are locally inducible leukocytic aggregates that form in chronically inflamed nonlymphoid tissues,49 can form in different organs in a context‐dependent manner through triggering of inflammatory circuits involving IL‐17, IL‐6, IL‐1β, and/or IL‐22.50-53 In terms of structural organization and FRC content, both nonclassical SLO (Figure 1B) and TLS (Figure 1C) exhibit a reduced complexity when compared to the classical SLO. We will focus our review here on FALC and inducible BALT as examples of nonclassical SLOs and TLS, respectively, to highlight the few knowns and many unknowns of FRC biology in these compartments. FALC are located beneath the mesothelium and are surrounded by adipose tissues. A clear structural segregation of lymphocytes is not recognizable with a dense cluster of B cells being intermingled with CD4+ T cells and CD11b+ myeloid cells.54, 55 The main B cell population within FALC are B1 B cells that patrol body cavities and are the source of natural, low‐affinity immunoglobulin M (IgM) antibodies that bind to pathogenic bacteria.56 FALC also contain innate lymphoid cells (ILC), particularly type 2 ILCs and NKT cells.47, 55 The production of CCL19 and CCL21 by FALC FRC most likely mediates the attraction and retention of naive T cells.54 PDPN‐expressing FRC that underpin FALC structures are highlighted by the Ccl19‐Cre transgene, express PDPN and occupy perivascular niches with a surface marker profile that resembles splenic PRC (ie, PDGFRα+VCAM‐1+ICAM‐1+).8 Although these cells do not display the general phenotype of MRC or FDC, FALC FRC have been shown to produce the B cell‐attractant CXCL13.57 Hence, it appears that the somewhat random mixture of T and B cells in FALC is due to a high versatility of FALC FRC which permits attraction and interaction with B cells, T cells, and myeloid cells. Clearly, FALC FRC—and probably as well the FRC underpinning intestinal isolated lymphoid follicles—can steer both innate and adaptive immune responses without forming distinct microenvironments such as germinal centers. The formation of TLS is frequently associated with chronic inflammatory and autoimmune diseases.3, 58 Importantly, in the context of cancer, the presence of TLS correlates with improved survival in a growing list of human cancers including breast cancer,59 lung cancer,60 oral squamous cell61 and Merkel cell carcinomas,62 and melanoma.63 Hence, it is tempting to speculate that TLS serve as inducible and transient outposts of the immune system to locally cope with ongoing immunological threats. Moreover, it appears that the coordination of immune cell interaction within these structures relies on organizational principles that are comparable to those in the classical SLO (Figure 1C). During tumor formation, TLS undergo a maturation process that has been suggested to start with the segregation of T‐cell and B‐cell areas in the perivascular space and progresses by the appearance of germinal centers.64, 65 The subsequent development of germinal centers in tumor TLS is accompanied by the appearance of CXCL13‐producing, CD21+ FDC networks both in human colorectal cancer65 and in squamous cell carcinoma of the lung.64 The presence of chemokine‐secreting FRC that underpin TLS has been demonstrated in a variety of models of chronic organ inflammation.52, 53, 66 The formation of inducible BALT in the lung has revealed that the activation of the innate immune system via lipopolysaccharide instillation can drive the formation of local TLS in an IL‐17‐dependent fashion,50 while this cytokine is not necessary to induce BALT formation following intranasal infection with a propagation‐deficient virus.67 Nevertheless, viral infection appears to be sufficient to induce highly organized BALT structures that contain B‐cell follicles underpinned by a network of CXCL13‐expressing FDC as well as CXCL12‐producing, yet undefined, reticular stromal cells.66 Furthermore, the bacterial infection with Pseudomonas aeruginosa triggers BALT formation in a TLR‐dependent manner leading to the emergence of CXCL12+ reticular cells that is dependent on γδ T cell‐derived IL‐17, while FDC fail to develop under these conditions.66 Overall, the emerging view is that remodeling and maturation of immune‐stimulating FRC is one of the initiating events in the establishment of an immune‐competent niche capable of recruiting and retaining disease‐relevant lymphocytes in TLS.3 Hence, targeted modulation of FRC differentiation processes within TLS may lead to treatment modalities that either attenuate TLS formation during chronic inflammatory diseases or foster the development of such immune‐activating structures in malignant diseases. 3 IMMUNE CELL‐FRC INTERACTIONS The main function of secondary lymphoid organs is to preempt68 and to deal with1 the encounter of microbial agents and tumor cells. Pathogens and other antigenic material arrive at the antigen‐sampling zone of SLO, eg, the subcapsular sinus region of lymph nodes, where dedicated macrophage/dendritic cell populations take up and transfer antigen to B cells.69, 70 Consequently, disruption of the subcapsular sinus structure results in defective immune responses during secondary infection in mice.71 The cellular infrastructure of the murine splenic marginal zone functions in the same manner and efficiently retains infectious agents.72 Interestingly, it appears that the function of antigen capture and innate immunological sensing in the marginal zone of murine spleens is assigned to CD169‐positive macrophages and/or dendritic cells,69, 72 while in the human spleen MAdCAM1‐positive MRC operate as coordinators of immune cell interaction and drivers of subsequent immune activation.24 Antigens are further dispersed in the lymph node through the lymphatic sinuses that pervade the lymph node parenchyma, and are taken up by distinct dendritic cell subsets for the delivery to CD8+ or CD4+ T cells.73 The interaction of dendritic cells and T cells depends on the infrastructure provided by TRC74 and is regulated by TRC‐derived factors such as CCL2175 or lysophosphatidic acid.76 The efficient interaction of T and B cells at the T‐B border during viral infection depends on the presence of BAFF‐producing FRC.44 Other FRC subsets contribute during the subsequent steps of B‐cell activation in lymph nodes including antigen presentation in the germinal center,42 regulating B‐cell migration during the germinal center reaction,18, 42 and establishing plasma cell competent microenvironments in the medulla.45 FRC can perform these multiple functions because they are able to integrate a variety of signals through sensing of innate immunological stimuli and the differentiation of cellular signals in their immediate environment (Figure 2A). In the following sections, we will summarize how FRC detect and process pathogen‐derived innate immunological signals and illustrate the molecular pathways employed by FRC to regulate adaptive immune responses in lymph nodes, Peyer's patches and FALC. 3.1 Innate immunological sensing by FRC FRC can directly recognize pathogens and their immune‐activating signals using various pattern recognition receptors and particular sets of immune‐activating molecules.6, 7, 77 The activation of in vitro cultivated FRC from SLO12 or FALC8 with various TLR ligands including lipopolysaccharide, poly(I:C), and zymosan leads to upregulation of adhesion molecules ICAM‐1 and VCAM‐1 and the secretion of inflammatory mediators such as CCL2, IL‐6, and TNF. In vivo, lymph node FRC react rapidly to systemic application of lipopolysaccharide with the activation of antigen presentation and type 1 interferon (IFN) pathways and alterations in the generation of extracellular matrix proteins including matrix metalloproteinase‐9, periostin, collagen type VI, and laminin α2.6 Direct ligation of TLR4 on FDC by lipopolysaccharide leads to increased expression of adhesion molecules and promotes the production of antigen‐specific antibodies when FDC are co‐cultured with B cells in vitro.78 Moreover, the activation of FDC by oxidized phospholipids, which function as endogenous TLR4 ligands, can foster the germinal center reaction by promoting higher rates of class‐switch recombination and somatic hypermutation in B cells.79 The formyl peptide receptor 2 that binds microbial products derived from Escherichia coli or Listeria, interacts with the endogenous ligand LL‐37 to enhance CXCL13 and BAFF production by FDC and thereby promotes B‐cell proliferation.80 Viruses can directly infect FRC as demonstrated for the lymphocytic choriomeningitis virus in mice14, 81 and human viruses including Chikungunya virus82 or Ebola virus.83 Complex immune cell interactions are triggered when intracellular viral RNA is recognized by FRC via TLR712 (Figure 2B). The transcriptomic analysis of lymph node FRCs after subcutaneous infection with herpes simplex virus‐1 (HSV‐1) revealed a pronounced activation of type‐I IFN pathway in FRC.77 Virus‐induced inflammation results in FRC proliferation and the induction of a substantial remodeling of the FRC landscape.35, 77 However, excessive activation of TLR7 ligands, eg, through internalization of ribonucleotide proteins complexes via CD21, can result in type 1 IFN production by FDC which supports the long‐lasting maintenance of the germinal center response and sustained production of antinuclear antibodies with perpetuation of a lupus‐like disease in mice.84 Hence, FRC activation through innate immunological pathways requires dedicated control mechanisms to avoid immunopathological sequela. Innate immunological recognition circuits are integrated intracellularly via particular molecular switches such as the myeloid differentiation primary response 88 (MYD88) protein85 and can be amplified by cellular receptors such as the type‐I IFN receptor (IFNAR).86 During infection with the murine cytomegalovirus, blockade of the type‐I IFN pathway leads to a change in viral tropism with a shift from subcapsular macrophages to MRC as the main target cells. The elevated infection rate of MRC leads to the activation and recruitment of NK cells, which efficiently reduce the viral burden in the subcapsular sinus but consequently destroy the reticular cell network of lymph nodes leading to systemic distribution of the virus.87 Overall, it appears that IFNAR signaling in the stromal cell compartment is important to contain viral replication in a broad range of experimental models. However, whether and to which extent IFNAR signaling in FRC directly contributes to the control of a viral infection has not been determined yet. Further FRC innate activation signals can be derived from immune cells that populate their particular microenvironmental niches. For example, in murine FALC, both FRC and hematopoietic cells attracted by FRC can serve as source for TNF8 (Figure 2C). Likewise, human tonsillar FRC respond in vitro to TNF exposure with increased expression of adhesion molecules and enhanced production of inflammatory cytokines.88 Further consequences of innate immunological sensing by FRC include the production of T cell‐activating factors such as IL‐33, which is produced by splenic PDPN+ FRC during vaccination with a recombinant viral vector.89 Single‐cell RNA‐seq analysis has revealed a population of FRC in naive lymph nodes that express high levels of Cxcl9.7 It appears that CXCL9 is mainly provided by stromal cells while CXCL10 is mainly express by murine myeloid cells DC following immunization of mice with dendritic cells that are pulsed with ovalbumin protein and activated with lipopolysaccharide and poly(I:C).90 In sum, FRC actively participate in the earliest phases of developing immune responses through their function as recipients of innate immunological signals and as coordinators of subsequent immune reactions through autocrine and paracrine signal amplification. 3.2 FRC control adaptive immune responses in lymph nodes and Peyer's patches Molecules of the TNF receptor superfamily are not only crucial for the formation of lymphoid organs2, 46, 68, 91 but also profoundly impact the maturation of myofibroblastic progenitors into fully immunocompetent FRC. For example, genetic ablation of lymphotoxin‐β receptor expression on Ccl19‐Cre+ FRC leads to defective FRC maturation with reduced expression of key molecules such as Ccl19, Ccl21, and Il7, that precipitates high susceptibility to viral infection due to impaired activation of T cells.16 While the lymphotoxin‐β receptor appears to affect the maturation of all FRC subsets in lymph nodes, other molecules from the TNF receptor superfamily appear to be required for subset specification. For example, FDC differentiation depends on TNF produced by B cells,92 while CD30 contributes to proper B‐ and T‐cell zone segregation that is associated with reduced PDPN expression on yet undefined FRC subsets.93 The intricate regulatory circuits of FRC‐immune cell interaction that found the basis of protective immune responses is highlighted in a recent study on intestinal Listeria monocytogenes infection in mice.94 Listeria infection induces intestinal epithelial cell proliferation and depletion of goblet cells, while CX3CR1+ myeloid cells in Peyer's patches produce IL‐23 and thereby activate IL‐17‐secreting γδ T cells. The resulting IL‐11 production by PDPN‐expressing cells in Peyer's patches facilitates the activation of enterocytes and limits intestinal villus invasion by Listeria.94 However, such protective FRC‐immune cell interactions may precipitate immunopathological consequences such as a decreased thickness of the mucus barrier that eventually fosters intestinal inflammation.94 Thus, FRC can function both as activating and regulating cellular entities during immune responses. The ability of FRC to negatively impact T‐cell responses has been first noted by the Turley group who demonstrated that FRC in lymph nodes can present peripheral tissue antigens to T cells and thereby attenuate self‐reactivity.95 It has been proposed that the generation of nitric oxide by lymph nodes FRC regulates the expansion and activity of T cells.96, 97 However, since nitric oxide can be produced by other lymph node stromal cells such as lymphatic endothelial cells,96 it remains to be determined, for example, through FRC‐specific ablation of the inducible nitric oxide synthase gene, to which extent FRC regulate T‐cell activity through this mechanism. It is also possible that FRC regulate global immune responsiveness by impacting regulatory T‐cell differentiation. It is generally assumed that dendritic cells are the main cell population that control the differentiation pathway of CD4+ T cells toward the FoxP3+ regulatory T‐cell phenotype.98, 99 However, a recent study suggests that FRC in mesenteric lymph nodes can modulate resident dendritic cells via a bone morphogenic protein‐2‐dependent pathway to foster the induction of regulatory T cells.21 Further studies are warranted to elaborate such direct and indirect pathways of FRC‐dependent immune regulation. Innate lymphoid cells (ILC) regulate immune responsiveness by bridging innate and adaptive immunity. In contrast to T and B cells, ILC lack rearranged antigen receptors and their development and activation is therefore mainly steered via soluble factors and their receptors. Since ILC are particularly abundant at mucosal sites, they are considered as the main cell population that maintains tissue integrity and homeostasis via innate immune mechanisms.100 ILC accumulation at mucosal surfaces relies on the provision of survival factors such as IL‐7 and IL‐15 that can be produced by FRC13, 101 However, ILC also reside in SLO where they are involved in the regulation of adaptive immunity.102, 103 Recently, it has been shown that group 1 ILC are localized in the T cell zones of Peyer's patches and that Ccl19‐Cre+ FRC generate an essential niche for these cells through the provision of IL‐15.12 However, IL‐15 production by PDPN+ FRC in Peyer's patches is rapidly abrogated under excessive inflammatory conditions such as infection with a cytopathic virus. Importantly, the swift cessation of IL‐15 production by FRC in Peyer's patches and mesenteric lymph nodes is dependent on MyD88 signaling which prevents an overshooting activation of NK1.1+ ILC and immunopathological overstimulation of IFN‐γ‐producing Th1 cells (Figure 2B). As a consequence, unrestrained Peyer's patch FRC lacking MyD88 expression permit the rapid clearance of a cytopathic viral infection through boosted ILC1 and Th1 responses which is accompanied by impaired intestinal integrity, bacterial dysbiosis, and chronical intestinal inflammation.12 This study shows that FRC in lymph nodes and Peyer's patches can act as immune rheostats through the regulation of group 1 ILC activity. It will be important to further elaborate the mechanisms that grant FRC in lymphoid organs control over innate and adaptive immune responses. 3.3 FRC‐dependent immune responses in FALC In case of a breach of pathogenic microorganisms into one of the body cavities, protective immunity needs to be mounted swiftly to prevent harm to the internal organs. The adipose tissue underlying the mesothelial surface of the pericardial, pleural and peritoneal cavities harbors variable numbers of FALC.104 In the omentum, a mesothelium‐covered tissue flap that connects stomach, pancreas, colon, and spleen, FALC have been shown to collect fluids and particles from the peritoneal cavity.105 The uptake of inflammation‐inducing substances from the peritoneal cavity such as lipopolysaccharide106 or the lipid‐based antigen zymosan47 induces an increase of omental FALC size and numbers. It has been shown that opsonization of bacterial antigens by natural, low‐affinity IgM antibodies generated by peritoneal B1 B cells can promote the uptake and elimination of bacteria by myeloid cells.107 Moreover, the presence of viral particles in the peritoneal cavity increases the cellularity and size of FALC with concomitant attraction of macrophages from the peritoneal cavity to these structures.108 Other immune cells in the peritoneal cavity such as B‐2 B cells109 or neutrophils110 reach FALC via the blood vasculature. Although FALC lack the compartmentalization observed in classical SLO, their structural foundations support the rapid generation of both T‐ and B‐cell immune responses. For example, intraperitoneal application of antigens such as ovalbumin leads to the initial activation of antigen‐specific CD4+ and CD8+ T cells in omental FALC.54 Similarly, T‐dependent and T‐independent B‐cell responses are generated first in FALC following intraperitoneal antigen application.47 The role of FRC in the initiation of adaptive immune responses in FALC has only recently been clarified. It appears that CXCL13‐expressing FRC in FALC not only support the attraction and retention of B cells,54, 57 but that Ccl19‐Cre+ FALC FRC can directly sense the presence of microbial products via TLR4 and initiate a MyD88‐dependent immune‐amplifying cascade8 (Figure 2C). Following exposure to TLR2 and TLR4 ligands FALC FRC secrete inflammatory cytokines and chemokines including CCL2 to attract CCR2+ inflammatory monocytes from the circulation.8 Inflammatory monocytes establish a crucial crosstalk with FALC FRC that leads to the rapid growth and remodeling of FALC. TNF functions as the main factor that regulates the reciprocal communication between FRC and the myeloid cells and eventually facilitates the generation of humoral immunity within FALC8, 47 (Figure 2C). Interestingly, although FALC lack FDC, the microenvironmental remodeling provided by FRC is sufficient to promote germinal center‐like B‐cell responses with class‐switch recombination and a discrete somatic hypermutation.47, 54 Currently, it remains unknown whether CXCL13+ and CCL19+ FRC represent two distinct cell types or whether a variable expression of the two chemokines represents different functional states. It will be possible to clarify this question by using appropriate cell fate mapping models to track the lineage commitments of FRC subsets within nonclassical SLO. Beyond their prominent function in the initiation and coordination of innate and adaptive immune responses in FALC, FRC present in visceral adipose tissues may also contribute to the maintenance of immune homeostasis and the regulation of the immune‐suppressive environment of adipose tissues under steady‐state conditions. Adipose tissues, including the omental fat favor the accumulation of IL‐10‐producing B cells111 and regulatory T cells.112 Regulatory T cells in adipose tissues are characterized by high expression of the IL‐33 receptor ST2,112 with IL‐33 being one of the main tissue factors that impacts the development and maintenance of regulatory T cells in this compartment.113 Since IL‐33 is mainly produced by FRC‐like cells in FALC,114 it is tempting to speculate that this circuit not only controls B1 B‐cell activation and local IgM production during lung infection and inflammation,114 but that FALC FRC equilibrate immune‐activating and ‐suppressive circuits in these tissues. The regulation of physiological functions by FRC‐derived IL‐33 in the adipose tissue may even extend to other body functions such a thermogenesis.115 Further studies will be required to better understand the molecular processes underlying FRC‐dependent immune activation in FALC. Moreover, it will be important to dissect the relation of FALC FRC to other PDPN expression fibroblasts in visceral adipose tissues and to elaborate the mechanisms employed by FRC that contribute to the maintenance of tissue homeostasis. 4 CONCLUDING REMARKS The translation of innate immune signals into activating or regulating processes that steer adaptive immune responses has been regarded as one of the main roles of professional APC such as dendritic cells. FRC as dedicated immune‐interacting fibroblasts have now entered the stage to be recognized as cells that crucially contribute to the decision‐making within the immune system. The many functions of FRC are accomplished through the generation of specific microenvironmental niches for various types of immune cells. Distinct subsets of FRC form these niches to support immune cell migration, survival, and differentiation. Interestingly, it seems that particular genetic programs are imprinted in the immune‐interacting fibroblasts depending on their anatomical location. The main differentiation switches of FRC differentiation have been identified with the lymphotoxin‐β receptor representing a necessary “signal 1” for FRC maturation in classical SLO.16 However, further research needs to dissect the intercellular communication pathways between FRCs and the various immune cells that impact the differentiation trajectories of FRC in lymphoid and nonlymphoid organs. Indeed, it appears that the intestinal lamina propria of patients suffering from inflammatory bowel disease harbors at least one mesenchymal stromal cell population that closely resembles lymphoid organ FRC and is highlighted by the expression of IL‐33 and Lysyl oxidases.116 Thus, understanding the mechanisms that govern FRC differentiation in SLO and TLS will, for example, open novel avenues to target drugable FRC differentiation pathways in TLS that form during human chronic inflammatory diseases such as rheumatoid arthritis117, 118 or Sjören's syndrome.119 A major challenge that should to be addressed in the future is the lineage relationship of FRC with other mesenchymal cell types such as adipocytes, chondrocytes, or regular tissue fibroblasts. The definition of mesenchymal cell types needs to be coupled to their development origin and their function within a tissue. Hence, a combination of single‐cell transcriptome analysis and faithful in vivo lineage tracing needs to be employed120 to obtain consistent definitions of the cell types that are currently covered by the broad terms “stromal cells” or “mesenchymal cells”. ACKNOWLEDGEMENTS We thank Dr. Natalia Pikor for critical reading of the manuscript. This study received financial support from the Swiss National Science Foundation (grants 166500 and 177208 to BL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CONFLICT OF INTEREST The authors declare no conflict of interest. REFERENCES
No comment yet.
Scooped by Gilbert C FAURE
June 22, 2019 5:49 AM
Scoop.it!

Neutrophil extracellular traps can activate alternative complement pathways - Wang - 2015 - Clinical & Experimental Immunology - Wiley Online Library

No comment yet.
Scooped by Gilbert C FAURE
June 20, 2019 3:16 PM
Scoop.it!

Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function

Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function | Immunology | Scoop.it
Genetic, pharmacological and metabolomics experiments reveal that the malate–aspartate shuttle and mitochondrial citrate export support the differentiation of mouse T helper 1 cells, whereas succinate dehydrogenase enforces their terminal effector function.
No comment yet.
Scooped by Gilbert C FAURE
June 20, 2019 1:37 PM
Scoop.it!

The immunobiology of MIF: function, genetics and prospects for precision medicine

The immunobiology of MIF: function, genetics and prospects for precision medicine | Immunology | Scoop.it
The pleiotropic cytokine macrophage migration inhibitory factor (MIF) is involved in the pathogenesis of autoimmune inflammatory disorders. This Review discusses MIF biology and signalling, its mechanisms of action and its involvement in rheumatic diseases, including opportunities for targeted therapies.
No comment yet.
Scooped by Gilbert C FAURE
June 18, 2019 2:45 PM
Scoop.it!

TOX is a critical regulator of tumour-specific T cell differentiation

Letter
No comment yet.
Scooped by Gilbert C FAURE
June 18, 2019 3:54 AM
Scoop.it!

Frontiers | Regulation of Innate Immune Responses by Platelets | Immunology

Frontiers | Regulation of Innate Immune Responses by Platelets | Immunology | Immunology | Scoop.it
The role of platelets has been extensively studied in the context of coagulation and vascular integrity. Their hemostatic imbalance can lead to known conditions as atherosclerotic plaques, thrombosis and ischemia. Nevertheless, the knowledge regarding the regulation of different cell types by platelets has been growing exponentially in the past years. Among these biological systems, the innate immune response is remarkably affected by the crosstalk with platelets. This interaction can come from the formation of platelet-leukocyte aggregates, signaling by direct contact between membrane surface molecules or by the stimulation of immune cells by soluble factors and active microparticles secreted by platelets. These ubiquitous blood components are able to sense and react to danger signals, guiding leukocytes to an injury site and providing a scaffold for the formation of extracellular traps for efficient microbial killing and clearance. Using several different mechanisms, platelets have an important task as they regulate the release of different cytokines and chemokines upon sterile or infectious damage, the expression of cell markers and regulation of cell death and survival. Therefore, platelets are more than clotting agents, but critical players within the fine inflammatory equilibrium for the host. In this review, we present pointers to a better understanding about how platelets control and modulate innate immune cells, as well as a summary of the outcome of thi
Gilbert C FAURE's insight:

other resources on https://www.scoop.it/topic/immunology?q=platelets

No comment yet.
Scooped by Gilbert C FAURE
June 17, 2019 2:23 AM
Scoop.it!

Exploring cellular variability in the immune system - origins, dynamics and clinical implications

event story...
No comment yet.
Suggested by Société Francaise d'Immunologie
June 16, 2019 5:45 AM
Scoop.it!

Concepts of GPCR‐controlled navigation in the immune system - Lämmermann - 2019 - Immunological Reviews - Wiley Online Library

Summary G‐protein–coupled receptor (GPCR) signaling is essential for the spatiotemporal control of leukocyte dynamics during immune responses. For efficient navigation through mammalian tissues, most leukocyte types express more than one GPCR on their surface and sense a wide range of chemokines and chemoattractants, leading to basic forms of leukocyte movement (chemokinesis, haptokinesis, chemotaxis, haptotaxis, and chemorepulsion). How leukocytes integrate multiple GPCR signals and make directional decisions in lymphoid and inflamed tissues is still subject of intense research. Many of our concepts on GPCR‐controlled leukocyte navigation in the presence of multiple GPCR signals derive from in vitro chemotaxis studies and lower vertebrates. In this review, we refer to these concepts and critically contemplate their relevance for the directional movement of several leukocyte subsets (neutrophils, T cells, and dendritic cells) in the complexity of mouse tissues. We discuss how leukocyte navigation can be regulated at the level of only a single GPCR (surface expression, competitive antagonism, oligomerization, homologous desensitization, and receptor internalization) or multiple GPCRs (synergy, hierarchical and non‐hierarchical competition, sequential signaling, heterologous desensitization, and agonist scavenging). In particular, we will highlight recent advances in understanding GPCR‐controlled leukocyte navigation by intravital microscopy of immune cells in mice. 1 INTRODUCTION Innate and adaptive immune responses depend on the coordination and spatiotemporal control of leukocyte dynamics between and within lymphoid organs and peripheral tissues. A wide spectrum of chemically diverse molecules including small proteins, peptides, lipids, nucleotides, and extracellular matrix fragments can act as chemoattractants, regulating leukocyte motility, migration, chemotaxis, positioning, and cell‐cell interaction. Leukocytes perceive these signals mainly through G‐protein–coupled receptors (GPCRs) that, upon agonist binding, induce intracellular promigratory responses.1, 2 Based on the cell type–specific expression of cell surface GPCR type combinations and intracellular GPCR‐controlling protein networks, each leukocyte subset has evolved specific trafficking paths to fulfill their designated effector functions in the body.3-5 Over the last decades, the analysis of GPCR‐deficient mouse models has advanced our understanding of how specific GPCR signals determine immune cell positioning and compartmentalization in situ. Recent work now also started to shed light on the establishment of chemokine patterns and chemotactic fields that guide leukocytes in mammalian tissues.6, 7 In particular, intravital imaging of control and GPCR‐deficient leukocytes in tissues of live anesthetized mice has brought unprecedented insight into the dynamic migration patterns of immune cell subsets in situ.8, 9 Despite these achievements, it is still largely unclear how leukocytes make directional decisions in lymphoid and inflamed organs where they constantly encounter GPCR signals emanating from multiple sources. The detailed mechanisms of how leukocytes sense, integrate, and prioritize between multiple chemotactic fields in situ and how this influences their physiological trafficking are still largely unknown. Dissecting these molecular events experimentally in mammalian tissues is very challenging and demanding. In particular, we are missing important pieces of information (eg, the exact distribution and concentrations of known chemottractant, GPCR dynamics in leukocytes) and cannot control for unknown chemotactic fields. Due to these current limitations many of the emerging concepts for leukocyte navigation in complex chemoattractant milieus come from studies in controlled in vitro systems2 or lower model organisms.10, 11 However, these concepts from reductionist models may not always be easily translatable to the complex situation in mammalian lymphoid organs and inflamed peripheral tissues. In recent years, several systematic studies in mice have started to disentangle how multiple GPCR signals shape leukocyte migration patterns in the complexity of mammalian tissues. In this review, we will summarize common concepts and mechanisms of GPCR‐controlled leukocyte navigation coming from studies with mouse and human leukocytes. We outline the protein networks that control GPCR signaling and GPCR activity and discuss how these may control leukocyte navigation strategies. In particular, we highlight our current knowledge on leukocyte navigation in complex chemoattractant fields and summarize them for three leukocyte subsets (neutrophils, T cells, and dendritic cells [DC]) with different physiological trafficking paths. For each cell type, we will critically evaluate the relevance of current concepts for leukocyte navigation in mouse tissue. While it is very likely that some navigation strategies are only relevant for certain immune cell types and adapted to specific physiological tissue environments, leukocyte subsets may also share basic strategies for directional decision‐making in lymphoid and inflamed tissues of mammals. 1.1 Concepts and mechanisms of GPCR‐controlled leukocyte navigation Many chemokines and chemoattractants are classical inducers of leukocyte polarity, adhesion, and locomotion. They act through GPCRs on intracellular signaling pathways to establish biochemical asymmetry within the cell, preceding the formation of a polarized cell with an actin‐rich front and a myosin II–rich rear.12, 13 Key molecular pathways involved in establishing functional polarity downstream of GPCRs in leukocytes depend on phosphoinositide 3‐kinases (PI3K) and members of the Rho family of small GTPases.14 Rac isoforms, Cdc42 and RhoA represent major signal hubs that act through several effector molecules to regulate actin polymerization and actomyosin cytoskeleton. The balanced interplay of these components shapes the typical amoeboid migration mode of each leukocyte subset.15, 16 In homogeneous fields of soluble chemokines and chemoattractants, most leukocytes undergo self‐polarization, before increasing their motility, migration speed, and movement in a random and undirected fashion (chemokinesis) (Figure 1A).17 Chemokinesis is considered a migratory pattern that helps leukocytes scan large tissue volumes. We have learnt from intravital microscopy studies in mice that lymphocytes show such continuous undirected (random‐walk) migration in lymphoid organs to enable encounters and interactions with other leukocytes.9 Together with other determining factors (eg, confinement between stromal tissue elements), uniform chemokine signals critically control chemokinesis by increasing the speed of randomly moving lymphocytes in situ.18 Once leukocytes perceive external gradients of soluble chemokines and chemoattractants, they can perform directional movement along the concentration gradients of these diffusing attractants (chemotaxis) (Figure 1B).17 Some leukocyte subsets have also been reported to be repelled from high chemoattractant concentrations (chemorepulsion), leading to their movement against the gradient (fugetaxis).19 However, the underlying molecular mechanisms of this process are still under investigation (Figure 1C).20, 21 Apart from soluble molecular cues, leukocytes also perceive surface‐bound attractants as gradients or as homogeneous fields and undergo movement along these surfaces in a directed (haptotaxis) (Figure 1B) or undirected manner (haptokinesis) (Figure 1A), respectively.16, 22 The aspect of leukocyte navigation along surface‐bound attractants is particularly relevant for chemokines with binding capacities to extracellular glycosaminoglycans (GAGs), which decorate many stromal cell elements in tissues.22, 23 This form of imprinting non‐diffusible chemokine gradients into the tissue has been shown critical for leukocyte trafficking across the blood endothelium and entry into lymphatic vessels.6, 23 The terms “chemotaxis” and “haptotaxis” subsume a spectrum of navigation strategies, which leukocytes can use to follow attractant gradients.24 When perceiving an external attractant gradient, some leukocytes (eg, unstimulated neutrophils in culture dish) undergo a full morphological change from unpolarized shape to the establishment of a front‐back axis, which then leads to directional movement along the gradient. In contrast, other leukocytes already migrate with pre‐established polarity (eg, DCs and neutrophils in 3D), before they steer along the gradient by redirecting their migration path. Alternatively, prepolarized leukocytes may move along a gradient without redirecting their path and start to accelerate the closer they get to the attractant source (eg, neutrophils in response to dying cells). Once at the highest attractant source, leukocytes may also actively decelerate and slow down their migration.24 As evidenced from intravital microscopy of select leukocyte subsets, we know that this spectrum of chemotactic responses also occurs in mouse tissues. While we acknowledge that chemokines and chemoattractants are central for many aspects of these migratory responses, we are missing a detailed understanding about how these signals shape the navigation of leukocytes in situ. Is the cellular movement guided by one or more attractant signal(s)? How do leukocytes navigate in complex gradient fields and sense the right direction? How do leukocytes sense their final destination and know where to stop? Are there inherent differences between leukocyte subsets in their navigation strategies? As many other cell types, leukocytes possess several mechanisms that directly regulate the functionality of GPCRs.13, 25-28 These are mainly controlled by GPCR interactions with three protein families: heterotrimeric (α, β, γ) G‐proteins, G‐protein–coupled receptor kinases (GRKs), and β‐arrestins. Upon stimulation, a GPCR functions as a guanine nucleotide exchange factor that catalyzes the exchange of GTP for GDP on Gα subunits of the heterotrimeric G‐protein. In leukocytes, Gα subunits of the pertussis toxin‐sensitive Gi subfamily play critical roles for the signaling of many chemokine and chemoattractant receptors. The dissociation of Gβγ from Gα‐GTP allows them both to independently activate downstream signaling pathways. Leukocyte chemotactic responses are largely controlled by the released Gβγ, which activates phosphoinositide 3‐kinase (PI3K) and phosphoinositide‐specific phospholipase Cβ (PLC)/inositol‐trisphosphate (IP3)/diacylglycerol effector pathways.29, 30 The termination of GPCR signaling relies on the intrinsic GTPase activity of the Gα subunit that hydrolyzes GTP and reassembles as Gα‐GDP with Gβγ to form an inactive heterotrimer. This Gα GTPase reaction is accelerated by a family of proteins, called “regulators of G‐protein signalling” (RGS proteins) to facilitate the rapid turning off GPCR signaling. Hence, RGS proteins are considered key desensitizers of G‐protein‐signaling pathways.27 In addition, another negative feedback loop evolved to prevent the overstimulation of cells through excessive GPCR stimulation. Following agonist binding and G‐protein activation, GPCRs become rapidly phosphorylated on their cytoplasmic tails and intracellular C‐termini by specific enzymes, usually members of the GRK family.31, 32 The pattern of receptor phosphorylation creates a barcode with high‐affinity binding sites for the recruitment of β‐arrestin proteins.33 As a consequence, the increased binding of β‐arrestin to the receptor sterically hinders the GPCR interaction with G‐proteins. This uncoupling of G‐proteins from the receptor, referred to as “receptor desensitization”, prevents further GPCR activation by repeated agonist stimulation over seconds to minutes.34 β‐arrestins can also control more long‐lasting desensitization of GPCRs over minutes to hours. As they can interact with clathrin‐coated pits, their binding to GPCRs also targets receptors for internalization. Besides, GPCR internalization can also follow other pathways (arrestin independent, clathrin independent) or not occur at all.35 Depending on the intracellular trafficking route, the internalized receptors may be subject to degradation, leading to the downregulation of cell surface GPCRs. Alternatively, targeting internalized GPCR to recycling endosomes and back to the plasma membrane can quickly replenish GPCRs on the cell surface.35 In addition to their important roles in receptor inactivation and internalization, GPCR‐recruited β‐arrestins also act as signaling mediators by directly coupling to numerous signaling molecules.36 At many GPCRs, β‐arrestin‐mediated signaling and classical G‐protein signaling can have distinct biochemical and physiological actions from one another. A relatively new paradigm on GPCR signaling considers the allosteric interaction among the ligand, the GPCR, and the transducers (β‐arrestins and GRKs) and how their contribution influences the bias for G‐protein– or β‐arrestin–mediated signaling.28 Resulting from this paradigm, the concept of biased agonism, ie, that different ligands at the same GPCR are able to activate some signaling pathways while blocking others, is of particular interest for many chemokine receptors with prominent roles in leukocyte navigation.37 In the following, we will point out the most commonly and recently discussed mechanisms, which would allow the control of leukocyte navigation. Given the before‐mentioned regulation mechanisms for GPCR functionality, a “One‐GPCR system” appears already sufficient to control chemokinesis and chemotaxis of leukocytes (Figure 2A‐E). To increase the sensitivity for attractant gradients, leukocytes can upregulate the cell surface expression of GPCRs. Some leukocytes store GPCRs in intracellular vesicles, which can fuse with the plasma membrane under conditions of leukocyte activation.38 While the release of GPCR from vesicular stores occurs within minutes to hours, most leukocytes often respond to external stimuli by changing their cell surface GPCR profile over hours to days. These changes are primarily based on the induction of gene‐transcription networks, which also include GPCR proteins, when leukocytes transition between cell states or undergo differentiation (Figure 2A). Multimerization of GPCRs, including homomerization of the same GPCR type, provides another level of GPCR regulation.25 A recent study highlighted the functional importance of GPCR oligomerization in promoting leukocyte chemotaxis (Figure 2B). By lowering cellular cholesterol, inflammatory stimuli enabled GPCR oligomers that acted as scaffolds for distinct promigratory signaling pathways to foster efficient leukocyte migration.39 However, GPCR multimerization has also been reported to dampen GPCR responsiveness.25 Several other mechanisms can attenuate the sensitivity of leukocytes for chemokines and chemoattractants. One involves the presence of a receptor antagonist that binds to the same GPCR as the gradient‐forming attractant agonist, but exerts blocking function for promigratory signaling (Figure 2C). More cell‐intrinsic mechanisms include the downregulation of GPCR expression by lowering GPCR mRNA stability40 or enhancing GPCR degradation.41 As discussed above, agonist‐induced receptor desensitization also attenuates the signaling responsiveness of GPCRs. Upon homologous desensitization, when GRKs phosphorylate agonist‐specific GPCRs, the further recruitment of β‐arrestins can lead to G‐protein uncoupling and internalization of GPCRs (Figure 2D). This process explains why many leukocyte chemotaxis responses toward single attractants are dose dependent and follow a bell‐shaped curve, with higher concentrations resulting in stasis.42 Homologous desensitization may be particularly relevant when leukocytes sense high attractant concentration in situ, eg, at the center of an attractant source.43 Under such conditions, the majority of cell surface GPCRs is likely to undergo desensitization, internalization, and degradation, which may then result in cellular unresponsiveness to continuous or repeated stimulation through the same attractant. As a strategy to remain responsive to subsequent stimulation in gradients, some leukocytes internalize GPCRs, deploy its ligand cargo into lysosomes, and quickly recycle unloaded GPCRs back to the plasma membrane.44 Thus, by eliminating chemotactic factors from the extracellular environments, classic GPCRs can acquire additional scavenging function. This “consumption” of external attractant may also impact the chemotactic milieu by reducing the strength of attractant cues.44 Instead of only binding one agonist, many “One‐GPCR systems” can bind and respond to two or more chemoattractants and activate downstream signaling (Figure 2E). Sensing these distinct attractants through the same GPCR in a spatial or temporal sequence can provide another navigation strategy. In our body, leukocytes are rarely exposed to only one chemotactic factor. For efficient trafficking between organs and coordinated movement within tissues, most leukocytes express more than one GPCR on their surface and sense a wide range of chemokines and chemoattractants. Directional decision‐making in lymphoid and inflamed organs requires leukocytes to constantly sense, compare, and integrate numerous GPCR signals emanating from multiple sources. To efficiently navigate in a complex milieu of attractant gradients, leukocytes need to respond to combinational signals and prioritize between competing signals. While this aspect of GPCR signal integration has already been of interest decades ago, it has regained momentum with the recent developments in fabricating microfluidic‐based chemotaxis devices. We will now briefly summarize common mechanisms and concepts for leukocyte navigation, which become already relevant in the presence of a second GPCR signaling system (“Two‐GPCR systems”) (Figure 3). As leukocytes often use combinations of more than two‐GPCR systems, these principles could be further expanded. Manifold scenarios of attractant interpretation are conceivable, when leukocytes sense two chemoattractant signals through two different GPCR types (Figure 3). The outcome for leukocyte guidance depends on several determining parameters: (a) the spatial distribution of each signal (uniform, graded), (b) the spatial orientation of both signals toward each other (same or opposing directions), and (c) the ratio of signaling input that leukocytes receive from both signals (equal, unequal). The latter point includes both cell‐intrinsic features and cell‐extrinsic conditions. Unequal signaling input can result from different cell surface expression of the two‐GPCR types or different strength of the downstream signaling pathway. In both cases, one chemoattractant signal dominates over the other. This can also occur in leukocytes with equal signaling input from both GPCR systems under conditions of unequal concentrations of both signals in the extracellular space. Many of these scenarios have already been addressed with select leukocyte subsets and their cell‐specific GPCR combinations in controlled in vitro microenvironments, and examples will be discussed in the next paragraphs about specific leukocyte subsets (neutrophils, T cell, and DCs). As discussed before, homogenous chemoattractant fields can induce leukocyte polarity and chemokinesis. A second‐graded signal “on top” can then redirect prepolarized leukocytes and guide them toward other locations. However, if the uniform attractant field is very potent, it will retain leukocytes and attenuate chemotaxis toward the second‐graded signal (Figure 3A).45-48 Under conditions when both attractant signals are oriented in the same direction and overlap, the two‐GPCR signals have usually additive effects for leukocyte chemotaxis (Figure 3B). In the case of promigratory signals, chemotactic factors act often synergistically to improve chemotaxis along the same direction.49 Physiologically, this might be of particular relevance for tissue sites where overlapping attractant gradients originate from the same local area. A special variant of GPCR signal synergism has initially been observed in migrating human and mouse neutrophil populations in vitro. During their chemotaxis in response to shallow N‐formyl‐peptides (fMLF) gradients, neutrophils released the lipid leukotriene B4 (LTB4) that acted on top of the early chemotactic factor as a signal relay molecule to improve chemotaxis of the whole neutrophil population.50 Under conditions when leukocytes encounter two spatially opposing gradients, the two‐GPCR signals compete for guiding leukocytes into one or the other direction (Figures 3C and 4). Leukocytes exposed to two opposing attractants with equal signaling strength will likely accumulate and find migratory equilibrium in the middle of both gradients (Figure 3C).47, 48, 51, 52 However, an unequal signaling input from both signals favors the movement of leukocytes into one direction (Figure 4A).47 It is known for decades that specific GPCR signals can dominate over other GPCR signals, which enables leukocytes to prioritize some chemoattractant signals over others (Figure 4B).42, 45 This aspect of GPCR crosstalk provided a first conceptual framework for neutrophils traveling in a stepwise fashion from the blood into infected tissues.45 Initially, it was discussed that heterologous desensitization of GPCRs might be an underlying mechanism for prioritizing chemotactic cues. In contrast to homologous desensitization (see above), heterologous GPCR desensitization is agonist independent and results from the phosphorylation of one GPCR by a kinase activated through the signaling cascade of another activated GPCR (Figure 3D). Thus, one‐GPCR signal can act as desensitizing signal for multiple other GPCR types, causing leukocytes to become refractory to several chemotactic stimuli within minutes. This rapid cross‐phosphorylation has been linked to second‐messenger kinases, particularly protein kinase C, which phosphorylates the GPCR at sites different from GRKs.53 For neutrophil navigation in opposing gradients, it was later proposed that the dominance of certain GPCR signals is regulated by events downstream of the receptors. According to this concept, referred to as “signaling hierarchy”, special GPCRs induce intracellular signaling pathways that can override signaling pathways downstream of other GPCR signals42, 54 (see below for details). Leukocyte populations in tissues rarely consist of identical cell clones, but are rather characterized by many cells with slightly heterogeneous expression of GPCR combinations. Thus, single‐cell heterogeneity on the basis of combinatorial GPCR expression may influence the population response in two opposing attractants with equal signaling strength (Figure 4C). In many physiological settings, leukocytes are thought to navigate step‐by‐step through sequential chemotactic fields. Under conditions of two spatially segregated chemotactic signals in sequence (Figure 3E), leukocytes may first move along a first attractant gradient (Figure 1A), and then subsequently sense the gradient of a second, more distant attractant. During the transition from first to second attractant gradient leukocytes then encounter a competitive situation between two gradients (Figure 3C). When the second signal is dominant over the first one, it is plausible that leukocytes are recruited to and then retained at the distant site. Importantly, even without any dominance between the signals, leukocytes can migrate away from a first attractant and travel toward a second, more distant attractant.45 In principle, this also allows leukocytes to leave chemotactic fields of high, saturating concentrations. Moreover, leukocytes remain responsive for additional attractant changes, while moving back and forth in the equilibrium between both gradients. Thus, interpreting two distinct signals in sequence allows efficient navigation patterns that are not possible with only one attractant presented in the same spatial array. We want to point out that the sequential sensing of attractant gradients can also be temporally controlled (Figure 3E). Leukocytes may undergo sensing of a first attractant gradient, while a second attractant arises newly in close vicinity. In the course of an immune response in lymphoid or inflamed tissues, this may result from chemoattractant secretion of nearby activated tissue‐resident cells or recently recruited, blood‐derived leukocytes. As most immune responses are choreographed by a sequence of timely separated cellular events, it is likely that this aspect of sequential sensing has strong influence on leukocyte navigation in situ. In our contemplation on leukocyte navigation by “Two‐GPCR systems”, we have focused until now on GPCRs with signaling function. However, many leukocyte subsets additionally express members of the atypical chemokine receptor (ACKR) family on their surface. Also referred to as scavenging receptors, ACKRs are GPCRs with promiscuous binding affinity for multiple chemokines. As they do not couple to G‐proteins, they are unable to induce intracellular signaling pathways. Instead, ACKRs can actively internalize and target chemokines for lysosomal degradation.55 Functional co‐expression of conventional chemokine receptors and ACKRs in leukocytes has been implicated in the fine‐tuning of leukocyte chemotaxis, with ACKRs acting as rheostats in restricting excessive migration in response to moderate chemokine levels (Figure 3F).56-58 As we have just outlined, leukocytes have evolved several molecular mechanisms that allow an enormous spectrum of GPCR‐controlled navigation strategies. Many of the emerging concepts for leukocyte navigation in complex chemoattractant fields have been developed in controlled in vitro systems, some of which by studying only one select leukocyte subset. Rigorous testing and proving the relevance of these concepts for leukocyte migration in the complexity of mammalian organs and tissues is technically very challenging. However, systematic studies in mice have started to delineate GPCR‐controlled navigation strategies and their influence on physiological trafficking patterns through lymphoid organs and inflamed peripheral tissues. In the following, we will discuss our current knowledge on the role of GPCR signals for the migration patterns of three leukocyte subsets (neutrophils, T cells, and DCs). Each of these immune cell types has evolved their own trafficking paths to fit their effector functions. We will highlight recent studies that conceptually advanced our understanding of GPCR‐controlled leukocyte navigation in mammalian tissues. 2 NEUTROPHILS Neutrophils are pivotal effector cells of our innate immune response and the first line of defense for eliminating bacteria and fungi in tissues.59 Recent studies also implicate regulatory functions of neutrophils in tissue homeostasis and cancer.60 In mammals, they are produced in the bone marrow and are continuously released into the bloodstream to patrol the intravascular compartment under homeostasis. Neutrophils circulate in the blood for ca. 12 hours under the influence of circadian rhythms, before they are mostly cleared into the bone marrow, but also other extramedullary tissues.61 In contrast to the general believe that naive peripheral tissues are free of neutrophils, recent work suggests that low numbers of neutrophils are present in many tissues under steady state.62 Upon inflammation and infection, the release of neutrophils from bone marrow increases their concentration in the blood by several folds.63 Moreover, large numbers of circulating neutrophils then infiltrate inflamed tissues where they sense activated vascular endothelium. In agreement with their critical role as first responders, neutrophils have evolved robust strategies to infiltrate inflamed tissues extremely fast and orient themselves to detect potential sites of microbial invasion with great precision. In many organs, the exit from the vascular compartment involves a sequence of exquisitely coordinated processes: (a) intravascular arrest, migration, and crawling along the activated endothelial cells, and (b) breaching multiple layers of the vascular wall (venular endothelium, venular basement membrane, and pericytes).64 Once neutrophils have traversed this barrier, they are primed for the rapid detection of damaged tissue or microbes in the extravascular space. At sites of cell death in the interstitial space, neutrophils undergo sequential phases of highly coordinated chemotaxis and cell cluster formation, now commonly referred to as neutrophil swarming.65, 66 As true sentinel cells, they sense almost any form of tissue insult, rapidly localize it in any inflamed organ and efficiently move toward the core of the inflammation or infection site. Neutrophils have been shown to express on their cell surface more than 30 GPCR types, which can all bind chemotactic molecules. Accordingly, neutrophils are responsive to a broad array of chemically diverse chemoattractants, including chemokines, lipids, complement factors, formylated peptides, nucleotides, alarmins, and proteolytic (ECM) fragments.67-69 Many of these chemotactic factors are usually present at sites of in vivo inflammation. How the crosstalk between these GPCR signals guides neutrophil recruitment in inflamed tissues has been of huge interest since decades. Early in vitro work with human polymorphonuclear neutrophils (PMN) characterized the strength of chemically distinct chemoattractant classes to desensitize calcium‐ion mobilization, as a read‐out of GPCR downstream signaling, to one another (Figures 2D and 3D).53, 70 Peptide chemoattractants, including N‐formylmethionyl‐leucyl‐phenylalanine (fMLF), the complement factor C5a, and the chemokine CXCL8 (IL‐8), cross‐desensitized one another to different extents (fMLF > C5a > IL‐8). Moreover, peptide chemoattractants, in particular fMLF, cross‐desensitized lipid chemoattractants, including platelet‐activating factor (PAF) and LTB4. In contrast, lipid and purinergic agonists failed to desensitize to the peptide chemoattractants.70 These results were extended to neutrophil chemotaxis in the presence of multiple chemoattractants, showing a hierarchy of resistance to competing signals, with fMLF and C5a inhibiting migration to other chemoattractants (Figure 3D).71, 72 Elegant under‐agarose chemotaxis experiments proposed the concept that neutrophils can navigate through complex chemoattractant fields by migrating in a step‐by‐step manner in response to one agonist source after another. Thus, their ultimate positions are determined combinatorially by the array of GPCRs they express and by the sequence of chemoattractant gradients they encounter (Figure 3E).45 In this concept, pathogen‐derived “end‐target” chemoattractants (N‐formyl peptides, C5a) will dominate over host tissue‐derived “intermediate‐target” chemotactic factors (CXCL8, LTB4) in their ability to guide neutrophil migration (Figure 3A, C, E).45 This dominance of end‐target attractants has been suggested to depend on the activation of the p38 MAPK pathway, which can override the phosphoinositide 3‐kinase (PI3K) pathway activated by intermediate‐target attractants.42, 54 Importantly, neutrophil navigation is also possible in a spatially sequential array of intermediate‐target chemoattractants (Figure 3E).45, 47, 51, 73 Another aspect of crosstalk between end‐target and intermediate‐target chemoattractants has not been considered in these early studies, but is also functionally relevant for neutrophil navigation. Already small amounts of fMLF or C5a can stimulate neutrophils to secrete intermediate‐target attractants, in particular LTB4.50, 74 This paracrine signaling mechanism becomes very relevant in chemotaxing neutrophil populations. Neutrophil‐released LTB4 functions as a signal relay molecule and amplifies in a feed‐forward manner the chemotactic response to subsaturating concentrations of end‐target attractants (Figure 3B).50, 75 Recent developments in microfabricated devices and microfluidic‐based chemotaxis systems now allow a more detailed analysis of neutrophil migration responses in complex chemoattractant milieus, providing deeper insight into neutrophil navigation in opposing gradients (Figure 3C),47, 73, 76-78 synergistic gradients (Figure 3B),49 and geometrically complex environments.49, 77 Moreover, even the analysis of GPCR signaling underlying neutrophil swarming dynamics is now possible due to novel micropatterning techniques.75 As human PMNs, mouse neutrophils express a range of functional GPCRs to sense N‐formyl peptides (through FPR1 and FPR2), C5a (mainly through C5ar1), LTB4 (mainly through LTB4R1/BLT1), and several chemokines including CXCL1, CXCL2, CXCL5 (through CXCR2), CXCL12 (through CXCR4), and several CC‐chemokines (through CCR1).67 Some of these GPCRs are present in secretory vesicles that can rapidly fuse with the plasma membrane upon neutrophil activation, allowing the cells to increase their responsiveness to chemotactic cues (Figure 2A).38 Other reported mechanisms to control GPCR functionality in neutrophils include competitive antagonism or partial agonism (Figure 2C),79 receptor multimerization (Figure 2B), differential agonist responses (Figure 2E),80 and agonist scavenging through simultaneous expression of ACKRs (Figure 3F).56 Homologous desensitization is a well‐known phenomenon for almost all neutrophil‐expressed GPCRs (Figure 2D). While GPCR transducers (G‐protein subunit types, GRKs, and arrestins) and RGS proteins have been linked to the function of some GPCRs in primary mouse neutrophils,32, 81-88 we are still missing a detailed understanding of their exact contributions to neutrophil navigation in complex chemoattractant fields. Clearly, neutrophils are equipped with many GPCR types and mechanisms to dynamically control GPCR activity, allowing them to use various navigation strategies in the presence of multiple chemotactic cues. Moreover, neutrophils have been shown to perform fugetaxis against the direction of a gradient of high concentration chemokine, a process that is mechanistically not well understood (Figure 1C).89 However, there are still many open questions of how these mechanisms contribute to the neutrophil migration patterns observed in situ. Intravital microscopy studies of GPCR‐deficient neutrophils provided novel insight into how GPCR signals choreograph the physiological trafficking paths of neutrophils. In the following, we will point out that GPCR signals are important throughout many steps in the lifecycle of a neutrophil. In particular, we will highlight studies that advanced our concepts of GPCR‐controlled neutrophil navigation in mouse tissues. 2.1 Bone marrow release: inhibiting chemokine‐mediated retention The majority of mature neutrophils in the body reside in the bone marrow, with an estimated ratio of 300:1 between neutrophils in the bone marrow and blood. Neutrophil release into the blood is controlled by the interplay of retention and mobilization signals, provided by two antagonistically operating chemokine systems (Figure 3A,C). During homeostasis, the chemokine CXCL12 is produced in the bone marrow and essential for the retention of mature neutrophils that express the corresponding chemokine receptor CXCR4.90 CXCL12 is expressed at highest levels by “CXCL12‐abundant reticular cells” (CAR cells), but also by other stromal cells of the bone marrow, including osteoblasts.63, 91 The expression levels of CXCL12 in stromal cells follow a circadian rhythm, controlled by the sympathetic nervous system.92 When neutrophils were freshly isolated from the bone marrow, they expressed only low levels of cell surface CXCR4, but contained high intracellular levels of CXCR4.90, 93 After placing these cells in medium lacking CXCL12, they upregulated cell surface CXCR4 within hours.90, 93 These findings suggested receptor desensitization and internalization in response to constitutively high local concentrations of CXCL12 in the bone marrow microenvironment (Figure 2D). Moreover, these data underlined that neutrophils receive constant CXCL12 signals, which position them in the bone marrow, probably by activating integrin‐mediated adhesion to stromal cells.94 While high concentrations of CXCL12 retain neutrophils in the bone marrow via CXCR4 signaling, low concentrations of CXCR2 ligands expressed on endothelial cells and produced by megakaryocytes facilitate neutrophil egress via CXCR2.63 Thus, CXCR2 signals recruit neutrophils out of the retentive CXCL12 field and direct them to the endothelial sinus walls for entry into the blood circulation (Figure 3A). This intricately balanced interplay between retention and mobilization signals can be shifted in both directions. G‐CSF treatment or acute inflammation, which increases blood serum levels of G‐CSF and CXCR2 ligands, shifts the balance toward neutrophil mobilization from the bone marrow.95-98 Several modes of action have been proposed for G‐CSF, either leading to the lowering of CXCL12 levels in the bone marrow or triggering the release of CXCR2 ligands from endothelial cells or megakaryocytes (summarized in63). The same shift toward neutrophil egress can be achieved by conditional gene depletions of CXCR4 or CXCL12 in mice.99, 100 The administration of the CXCR4 antagonist AMD3100 also results in a threefold increase in the number of circulating neutrophils and a corresponding decrease in bone marrow numbers.93, 101 Originally, this drug effect was interpreted as direct antagonism of CXCR4 expressed by neutrophils, thereby disrupting the CXCL12‐CXCR4 axis in the bone marrow (Figure 2C).90 Surprisingly, subsequent studies found that AMD3100 also acted on CXCR4 expressed by bone marrow endothelial cells, and inhibited the translocation of CXCL12 across bone marrow endothelial cells, suggesting a rapid rise of CXCL12 in the blood and reversal of the CXCL12 gradient (Figure 3B).102, 103 These data were questioned by intravital imaging studies that could not observe clear neutrophil egress from the bone marrow upon AMD3100 treatment. Instead, the increase in circulating neutrophils through AMD3100 was explained by the release of marginated neutrophils from the lung microvasculature.104 Moreover, AMD3100 had a blocking effect on the trafficking of aged blood neutrophils, which upregulate CXCR4 expression over time, enabling them to home back to the bone marrow for clearance.104 The exact mode of action of AMD3100 is still controversially discussed.90 Insight into the physiological consequences of shifting the chemokine balance in the opposite direction, toward retention in the bone marrow, comes from an extremely rare congenital human immunodeficiency disease. Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is an autosomal dominant human disorder caused by gain‐of‐function mutations in the C‐tail of CXCR4.105, 106 WHIM syndrome involves myelokathexis, a condition characterized by the retention of mature neutrophils in the bone marrow and peripheral neutropenia. WHIM‐associated truncations or mutations in the carboxy‐terminal tail of CXCR4 result in the loss of multiple serine residues, which are target sites for GRK‐mediated receptor phosphorylation. Truncated forms of CXCR4 are impaired in agonist‐induced homologous desensitization and internalization, and cause enhanced signaling upon CXCL12 stimulation.106 This leads to stronger anchorage of mature neutrophils in the bone marrow, counteracting CXCR2‐mediated chemotaxis toward vessels and neutrophil egress. However, administration of G‐CSF or ADM3100 to WHIM patients can overcome this imbalance and cause an increase in circulating neutrophil numbers.106 2.2 Getting to the site of inflammation: navigation along multiple chemokine fields Blood‐circulating neutrophils detect sites of tissue injury and infection by interacting with the luminal surface of activated venular endothelium. In response to tissue‐released inflammatory cytokines, endothelial cells upregulate P‐selectin, E‐selectin, and integrin ligands, such as ICAM‐1 and VCAM‐1, to promote interactions between neutrophils and the vessel wall. This induces neutrophils to undergo a multistep adhesion cascade along the endothelial lining before emigrating from the vessel into the inflamed tissue interstitium.107 Chemokines are present on the luminal surface of endothelial cells and cause arrest of rolling neutrophils by triggering the activation of integrins. Many studies showed an involvement of CXCR2 ligands, in particular CXCL1, but also CXCL2 and CXCL5, in this process.108, 109 These chemokines are primarily expressed and released by endothelial cells,110, 111 but also tissue‐resident cells, including pericytes, perivascular macrophages, and mast cells, can act as important chemokine sources.112-115 Due to their high‐affinity binding sites for heparin sulfate (HS) GAG most chemokines become immobilized by HS GAG on the luminal side of the endothelium,116 and defects in HS GAG synthesis have been shown to decrease immobilization of chemokines and neutrophil transmigration into inflamed tissues.117, 118 While the involvement of chemokines for neutrophil transmigration is widely established, there has been ongoing debate whether and how leukocytes sense stable chemokine gradients across the vessel wall on their way into the tissue (Figure 1B). There are ample references to support the common believe that chemotactic gradients between the apical and basolateral part of postcapillary venules promote diapedesis, ie, the outward passage of neutrophils through the vessel wall. Immunofluorescence stainings of HS GAG moieties revealed steep gradient of HS GAG scaffolds between the luminal and abluminal aspect of skin postcapillary venules.119 Under inflammatory conditions, HS GAG distribution became even more polarized by massive depositions of HS and laminin in the basolateral basement membrane of skin vessels.119 Given the GAG‐binding properties of many chemokines, it was proposed that these sharp HS GAG scaffold gradients might favor chemokine gradients across the venular wall. In agreement with this idea, excessive deposition of the GAG‐binding chemokine CXCL1 on the apical part of inflamed blood vessels resulted in decreased neutrophil diapedesis.120 Other supporting data come from experiments in which an extravascular source of CXCR2 ligands was placed in form of a gel on one side of a blood vessel.121 Under these conditions, neutrophil crawling was directed to emigrate preferentially from that side of the vessel. HS GAG on the surface of the endothelium was required to present CXCL2, forming a chemotactic gradient that was followed by neutrophils. This sequestration of endothelial chemokine occurred exclusively in venules, but not other blood vessel types.121 HS GAG, together with the atypical receptor ACKR1, was also discussed to establish gradients by transcytosis of chemokines.118, 122, 123 Transcytosis involves the internalization and transport of tissue‐derived inflammatory chemokines from the basal surface onto the luminal surface of endothelial cells. ACKR1 is specifically expressed by postcapillary venules and was shown to support promigratory chemokine patterns across the vessel wall for optimal leukocyte migration across the vessel wall.123, 124 Unlike other ACKR, ACKR1 does not act as classical scavenger receptor, and was initially discussed to promote the transcytosis of tissue‐derived inflammatory chemokines from perivascular pools to the apical surface of venules.122, 123 Novel insight into the functional role of ACKR1 and the directional cues that guide neutrophils during diapedesis come from recent elegant experiments of Nourshargh and colleagues.125 By studying TNF‐induced neutrophil emigration in the inflamed mouse cremaster muscle, it was shown that neutrophils encounter the two CXCR2 ligands CXCL1 and CXCL2 in a sequential manner during their passage through the vessel wall. In a three‐step process, neutrophils first sense CXCL1 produced by TNF‐stimulated endothelial cells on the luminal surface of venules, promoting crawling along the endothelium. Next, neutrophils encounter CXCL2 that is retained at endothelial cell junctions by ACKR1. Notably, CXCL2 is secreted by neutrophils themselves and then presented by ACKR1, which is enriched in endothelial junctions. This self‐guided migration response of neutrophils was critical for breaching of endothelial junctions and unidirectional transendothelial migration. Lastly, CXCL1 expressed by pericytes governed neutrophil crawling in the subendothelial space.125 While earlier work indicated relatively restricted expression of CXCL1 to vascular and tissue‐resident cells, and CXCL2 with activated neutrophils,126 these novel findings highlight unexpected non‐redundant roles for CXCL1 and CXCL2 to guide neutrophils through venular walls as governed by their distinct cellular sources.125 Having identified this critical spatiotemporal sequence of chemokine‐guided steps across the vessel wall (Figure 3E), it will be of future interest to understand how other tissue‐derived attractant signals may act on top of this and support further guidance into the underlying inflamed interstitium. As an example, neutrophils entering an inflamed peritoneum were suggested to encounter two sequential gradients in a step‐by‐step manner (Figure 3E).114 In a lipopolysaccharide‐induced peritonitis model, initial recruitment of neutrophils out of the blood vessel into the peritoneal tissue was regulated by rapid secretion of CXCL1 and CXCL2 from perivascular mast cells. Further guidance of extravasated neutrophils through the interstitium and into the peritoneal cavity depended on CXCL1 and CXCL2 produced by tissue‐resident interstitial macrophages.114 2.3 Getting to the site of inflammation: interpreting temporal cascades of chemically distinct chemoattractants Most of our discussions until now focused on the role of chemokines for neutrophil guidance in the tissue, but also putative non‐GAG‐binding, soluble chemoattractants including C5a, LTB4, and formylated peptides are sensed by neutrophils and relevant for special types of inflammatory reactions. A mouse model of autoimmune rheumatoid arthritis, the K/BxN serum transfer model, has provided unprecedented insight into how four different chemoattractant receptors, C5aR1, LTB4R1, CCR1, and CXCR2, collaborate to recruit neutrophils into the inflamed tissue.127 In this model, the inflammatory response is driven by immunoglobulin G autoantibodies to the ubiquitous glycolytic enzyme glucose‐6‐phosphate isomerase (GPI) leading to the formation of immune complexes that drive immune cell activation. Neutrophil infiltration into the joint is critical for the clinical signs of arthritis in this model. Several consecutive studies have elucidated a temporal cascade in which neutrophils encounter complement, lipid, and chemokine signals to enter the joint and contribute to disease progression (Figure 3E).74, 128-131 While it has long been known that immune complexes lead to the activation of the alternative complement system in arthritis,132, 133 it has only recently been found that C5aR signaling in circulating neutrophils is the key initiator for a cascade of events that ignite inflammation.131 The deposition of immune complexes in the joint space induces the generation of C5a, which unexpectedly binds to HS GAG on the synovial endothelium. Neutrophils sense C5a on the joint endothelium, induce integrin‐dependent arrest, and facilitate crawling along the vasculature. Subsequently, C5a signals stimulate neutrophils to secrete LTB4, which induces the entry of the first neutrophils into the joint and initiates the onset of disease.74, 128, 129, 131 After disease onset, recruited neutrophils in the joint secrete IL‐1β, which in turn stimulates fibroblast‐like synoviocytes to produce CCR1 ligands at first and later CXCR2 ligands.130 CCR1 ligands are required to recruit the next wave of neutrophils into the joint, and this recruitment of neutrophils is broadly amplified in the last step of the cascade when neutrophils themselves release CXCL2 to potently attract large numbers of neutrophils into the joint.67, 130 Thus, neutrophil entry into the inflamed joint is a prime example where neutrophil recruitment is choreographed by non‐redundant roles of distinct chemoattractants that collaborate sequentially in a temporal cascade (Figure 3E). Moreover, this process highlights the rapid production of complement and LTB4 to initiate a recruitment cascade at the local site of inflammation. By contrast, chemokines act later in this cascade to amplify and prolong the inflammatory response.67 2.4 At the site of inflammation: synergism through lipid‐mediated amplification Another example where complement‐induced LTB4 secretion rapidly shapes neutrophil migration patterns has recently been described.134 In a simplified fungemia mouse model, the fungi Candida albicans sequestered in the pulmonary vaculature and actively recruited neutrophils. Neutrophils showed swarm‐like migration patterns in response to sequestered yeast, similar to previously described swarming responses in other tissues.66 A small number of lung neutrophils responded within minutes and performed intravascular chemotaxis, before larger numbers of neutrophils were recruited and formed cell clusters. The immediate capture of live C. albicans by neutrophils depended on complement‐mediated chemotaxis.134 In addition, complement activation stimulated neutrophils to secrete LTB4, which amplified the directional recruitment and clustering of neutrophils in a synergistic manner (Figure 3B). This was in agreement with a previous study highlighting the importance of LTB4‐mediated signal amplification during neutrophil swarming in interstitial tissue spaces at sites of sterile skin injury and in bacteria‐infected lymph nodes.135 Neutrophil swarming is an essential process of the neutrophil tissue response and has been observed in diverse tissues under conditions of sterile inflammation and infection with various pathogens, including bacteria, fungi, and parasites.65, 66 The swarming response comprises sequential phases of highly coordinated chemotaxis followed by neutrophil accumulation and the formation of substantial neutrophil clusters, which has led to the multistep attraction model of neutrophil swarming.66 While the underlying signals and molecular players for some of these steps are still unclear, we know that neutrophil‐derived LTB4 acted on top of early released, yet unknown, chemoattractants and mediates intercellular signal relay among neutrophils to amplify interstitial recruitment in a feed‐forward manner (Figure 3B). This model was in accordance with earlier in vitro studies identifying LTB4 acted as a signal relay molecule (see above).50 As a consequence, LTB4‐LTB4R1 signaling enhances the radius of neutrophil recruitment from distant tissue sites and maintains the amplified chemotactic response of the neutrophil population. Together with signaling through other GPCRs, such as CXCR2 and FPR2, LTB4R1 signaling also optimizes neutrophil clustering.135 Importantly, LTB4 and CXCR2 signals are also relevant for the swarming response of human neutrophils.75 The formation of focalized dense neutrophil aggregates is considered beneficial for isolating sites of tissue wounding from viable surrounding tissue, containing microbial invaders and concentrating the microbicidal activity of a whole neutrophil population in one swarm center.66 However, neutrophil aggregation can also lead to tissue damage and removal of other cells.135, 136 In the context of the lung microvasculature, intravascular neutrophil swarms that formed in response to C. albicans infection lead to vessel occlusion and pulmonary hemorrhages, which were reverted in the absence of LTB4R1.134 How neutrophil‐derived LTB4 shapes and maintains a promigratory chemotactic field in vivo remains unclear. LTB4 is considered to have a short half‐life and can be rapidly turned into LTB4 metabolites, which act as natural inhibitors of LTB4‐mediated responses. However, it has also been demonstrated that neutrophils release LTB4 in form of exosomes, which may support more prolonged effects of LTB4 gradients.137 Interesting insights into this issue come from studies with diabetic mice receiving skin infections with methicillin‐resistant Staphylococcus aureus (MRSA), which leads to large neutrophil clusters in form of abscesses.138 Diabetic mice produce higher levels of LTB4 in the infected skin compared to non‐diabetic mice. Surprisingly, neutrophils in the skin of these mice failed to assemble into an organized abscess, as excessive LTB4 levels likely disrupted chemoattractant gradients in the skin and impaired directed neutrophil chemotaxis.138 These findings exemplify that the appearance or absence of neutrophil swarms depends on the specific mixture of chemoattractants in a specific inflammatory environment. Although not yet studied in detail, we know that several factors, including tissue damage size, presence of pathogens, induction of cell death, and neutrophil numbers, are important for shaping the exact neutrophil‐swarm phenotype in an inflamed tissue. All these factors can potentially initiate the release of chemotactic fields that may strengthen or attenuate LTB4‐mediated signal amplification in situ.66 2.5 Getting to the site of inflammation: following hierarchies True prioritization of chemoattractant fields has been observed for neutrophils in a model of thermal‐induced liver injury.139 In this model, large numbers of neutrophils are recruited over hours from the liver sinusoids to a focal site of sterile hepatic necrosis. The necrotic area releases several molecules that shape the adjacent hepatic environment and ultimately form two distinct chemotactic fields at different distances from the necrotic focus. During their search for damaged tissue neutrophils sequentially navigate through these two chemotactic fields. First, neutrophils follow an intravascular gradient of GAG‐bound immobilized CXCL2 that supports integrin‐dependent crawling toward the necrotic focus. This CXCL2 haptotactic gradient abruptly halts, approximately 150 μm proximal to the border of the necrotic tissue. Second, neutrophils at this border continue to migrate on top of platelets along non‐perfused vasculature, before entering the necrotic area.139, 140 When neutrophils were lacking the formyl‐peptide receptor FPR1, they migrated along the healthy sinusoids to the highest concentration at the end of the haptotactic CXCL12 gradient and never entered into the platelet‐rich and following necrotic zone. Given the important role of FPR1 signaling during this process, mitochondrial‐derived formyl peptides released from dying hepatocytes were suggested to attract neutrophils into the necrotic area. Of interest, FPR1 signaling has also been shown to regulate neutrophil recruitment into necrotic areas of hepatic ischemia‐reperfusion injury.141 In contrast to formyl peptides released from bacteria, endogenous formyl peptides are produced by mitochondria and become released upon cellular damage.142 Similar to bacterial formyl peptides, also mitochondrial formyl peptides can promote neutrophil chemotaxis in an FPR‐dependent manner.139, 142 Thus, neutrophil navigation in the liver injury model follows a spatial cascade of chemoattractants (Figure 3E) and appears to depend on the prioritization of an end‐target attractant (eg, fMLF) over an intermediate‐target attractant (eg, CXCL2) (Figure 3A). Recent elegant work by Kubes and colleagues revealed that neutrophils play a critical role in fully repairing the hepatic injury. In the course of this process, neutrophils at the border of the injury left the injury site and reentered healthy liver sinusoids.143 However, it remains to be shown if GPCR‐controlled mechanisms are involved in this form of reverse migration into the vasculature. 3 T CELLS T cells and B cells represent the cellular hallmark of the adaptive immune system. These lymphocytes are generally long‐lived cells and are driven by GPCR‐mediated guidance throughout their life cycle. Being released from the bone marrow as a common lymphoid progenitor, T‐cell precursor settle in the thymus where they tread a highly regulated developmental path, guided by GPCRs. Once T cells have been fully matured and selected, they exit the thymus and commence their recirculation pattern between secondary lymphoid organs (SLO). As the T‐cell receptor (TCR) repertoire needs to be highly diverse in order to raise the chance to efficiently detect foreign antigens against all kind of pathogens, the naive T‐cell precursor frequency for a specific antigenic determinant is very low (≈1/105‐1/106). Consequently, during a newly arising infection, antigen‐presenting DC need to interact with millions of T cells in order to activate the few rare naive T cells that optimally react to the foreign antigenic determinant. To facilitate this process T cells need to efficiently migrate between and navigate within SLOs to optimize such DC encounters. Once T cells are activated and primed by a DC carrying and displaying the proper antigen, they differentiate and change their GPCR expression pattern in order to leave the SLO and enter infected tissues via the blood stream. Here, GPCRs pilot them toward infected cells where they execute their specific effector function in order to eliminate or at least control the microbial invasion. In vitro experiments to address how lymphocytes respond to chemokines were primarily based on transwell, under agarose assays or 3D ECM‐like gels, showing that chemokinesis, chemotaxis, and homologous and heterologous desensitization apply to GPCR‐mediated navigation of T cells.144-149 However, these approaches have limitations when trying to address how T cells respond to more complex chemokine fields involving multiple GPCRs. With the development of microfluidic devices150 and more recently, microfluidic mazes, T‐cell exploratory patterns and chemotaxis in response to chemokines could be analyzed in more detail, while providing the investigator with a higher level of control and precision.151 Overall, however, there are only a few studies that have addressed complex GPCR interactions in T cells in vitro. In the following sections we will focus on what we have learned from in vivo experiments regarding the trafficking of T cells. 3.1 Searching for the antigen: exploration and compartmentalization In vivo, chemo‐ and haptokinesis are particularly prevalent in lymphoid organs and underlie the continuous undirected or random‐walk migratory activity of lymphocytes (Figure 1A).9 Functionally, this migratory behavior is required to enable encounters and consecutive interactions between leukocytes. In other words it reflects the search strategy of lymphocytes to detect rare interaction partners in a large and densely populated three‐dimensional space. Given the low precursor frequency of ly
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
July 9, 2019 11:40 AM
Scoop.it!

Objectives and research challenges in radioimmunotherapy: An overview

Objectives and research challenges in radioimmunotherapy: An overview | Immunology | Scoop.it
Objectives and research challenges in radioimmunotherapy: an overview, cynthia Keen...

Via Krishan Maggon
No comment yet.
Scooped by Gilbert C FAURE
June 26, 2019 1:26 PM
Scoop.it!

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses | JEM

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses | JEM | Immunology | Scoop.it

Studies of patients with loss of IL-6R function therefore provide a unique opportunity to establish the role for IL-6 in these disorders and define how impaired IL-6 signaling impacts human health.

No comment yet.
Scooped by Gilbert C FAURE
June 25, 2019 2:23 AM
Scoop.it!

Frontiers | Aging, Obesity, and Inflammatory Age-Related Diseases | Immunology

Frontiers | Aging, Obesity, and Inflammatory Age-Related Diseases | Immunology | Immunology | Scoop.it
The increase in the preva¬lence of obesity represents a worldwide phenomenon in all age groups and is pathologically and genetically correlated with several metabolic and cardiovascular diseases, representing the most frequent age-related diseases. Obesity superimposed on aging drastically increases chronic low-grade inflammation (inflammaging), which is an important link between obesity, insulin resistance, and age-associated diseases.Immune cells of both the innate and adaptive immune systems infiltrate the adipose tissue (AT) and during obesity induce inflammatory responses associated with metabolic switches and changes in phenotypes and function of immune cell subsets.Obesity poses new health problems especially when it occurs in the context of other diseases, many of them frequently affect elderly subjects. An emerging problem is the decreased proportion of patients with obesity achieving clinical response to therapy. In this review we will discuss the reciprocal influences of immune cell and AT inflammation in aging and age-associated diseases and the complex relationship of nutrient and energy-sensing homeostatic checkpoints which contribute to shape the phenotype of the AT. We will specifically examine Type-2 Diabetes, Rheumatoid Arthritis, Osteoarthritis, cognitive impairment and dementia, where obesity plays a significant role, also in shaping some clinical aspects.
No comment yet.
Scooped by Gilbert C FAURE
June 24, 2019 1:28 PM
Scoop.it!

Frontiers | Determinants for Neoantigen Identification | Immunology

Frontiers | Determinants for Neoantigen Identification | Immunology | Immunology | Scoop.it
All tumors accumulate genetic alterations, some of which can give rise to mutated, non-self peptides presented by human leukocyte antigen (HLA) molecules and elicit T-cell responses. These immunogenic mutated peptides, or neoantigens, are foreign in nature and display exquisite tumor specificity. The correlative evidence suggesting they play an important role in the effectiveness of various cancer immunotherapies has triggered the development of vaccines and adoptive T-cell therapies targeting them. However, the systematic identification of personalized neoantigens in cancer patients, a critical requisite for the success of these therapies, remains challenging. A growing amount of evidence supports that only a small fraction of all tumor somatic non-synonymous mutations identified represent bona fide neoantigens; mutated peptides that are processed, presented on the cell surface HLA molecules of cancer cells and are capable of triggering immune responses in patients. Here, we provide an overview of the existing strategies to identify candidate neoantigens and to evaluate their immunogenicity, two factors that impact on neoantigen identification. We will focus on their strengths and limitations to allow readers to rationally select and apply the most suitable method for their specific laboratory setting.
No comment yet.
Suggested by Société Francaise d'Immunologie
June 23, 2019 2:42 PM
Scoop.it!

Resolvin D1 promotes the targeting and clearance of necroptotic cells

Resolvin D1 promotes the targeting and clearance of necroptotic cells | Immunology | Scoop.it
Article...
No comment yet.
Suggested by Société Francaise d'Immunologie
June 22, 2019 2:19 PM
Scoop.it!

Lugdunin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors

Lugdunin amplifies innate immune responses in the skin in synergy with host- and microbiota-derived factors | Immunology | Scoop.it
Lugdunin is a peptide antibiotic produced by the skin commensal Staphylococcus lugdunensis. Here, the authors show that lugdunin reduces Staphylococcus aureus colonization in human keratinocytes and mouse skin by inducing the expression of human LL-37 and recruitment of monocytes and neutrophils.
No comment yet.
Scooped by Gilbert C FAURE
June 21, 2019 11:35 AM
Scoop.it!

Frontiers | Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions | Immunology

Frontiers | Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions | Immunology | Immunology | Scoop.it
Osteoclasts (OCLs) are key players in controlling bone remodeling. Modifications in their differentiation or bone resorbing activity are associated with a number of pathologies ranging from osteopetrosis to osteoporosis, chronic inflammation and cancer, diseases that are all characterized by immunological alterations. Therefore, the 2000s were marked by the emergence of osteoimmunology and by a growing number of studies focused on the control of OCL differentiation and function by the immune system. At the same time, it was discovered that OCLs are much more than bone resorbing cells. As monocytic lineage-derived cells, they belong to a family of cells that displays a wide heterogeneity and plasticity and that is involved in phagocytosis and innate immune responses. However, while OCLs have been extensively studied for their bone resorption capacity, their implication as immune cells has been neglected for a long time.In recent years, new evidences pointed out that OCLs play important roles in the modulation of immune responses toward immune suppression or inflammation. They highlighted their capacity to modulate T cell activation, to efficiently process and present antigens as well as their ability to activate T cell responses in an antigen-dependent manner. Moreover, very much like other monocytic lineage cells such as macrophages, monocytes and dendritic cells, OCLs display a phenotypic and functional plasticity participating to their anti-inflammatory o
No comment yet.
Scooped by Gilbert C FAURE
June 20, 2019 2:03 PM
Scoop.it!

Signature of an ineffective immune response to cancer revealed

Signature of an ineffective immune response to cancer revealed | Immunology | Scoop.it
Our immune system is programmed to destroy cancer cells. Sometimes it has trouble slowing disease progression because it doesn't act quickly or strongly enough. In a study published in The Journal of Clinical Investigation, ...
No comment yet.
Scooped by Gilbert C FAURE
June 19, 2019 1:49 PM
Scoop.it!

The emerging role of IL-26 in fighting against intracellular microbes | Immunopaedia

The emerging role of IL-26 in fighting against intracellular microbes | Immunopaedia | Immunology | Scoop.it
Dang et al., utilised the human leprosy model to showcase the ability of IL-26 to provide protection against intracellular bacteria. This research opens up the possibility for Th17 cells to also participate in immune defence mechanisms against not only extracellular, but also intracellular bacteria.
No comment yet.
Scooped by Gilbert C FAURE
June 18, 2019 7:45 AM
Scoop.it!

Photoimmunology: how ultraviolet radiation affects the immune system

Photoimmunology: how ultraviolet radiation affects the immune system | Immunology | Scoop.it
Ultraviolet radiation (UVR) modulates innate and adaptive immune responses at both local and systemic levels; understanding the mechanisms of this immunomodulatory capacity can explain how UVR has both beneficial and detrimental effects.
No comment yet.
Suggested by Société Francaise d'Immunologie
June 18, 2019 2:44 AM
Scoop.it!

Roles of Type 1, 2, and 3 Innate Lymphoid Cells in Herpes Simplex Virus 1 Infection In Vitro and In Vivo | Journal of Virology

Roles of Type 1, 2, and 3 Innate Lymphoid Cells in Herpes Simplex Virus 1 Infection In Vitro and In Vivo | Journal of Virology | Immunology | Scoop.it
ABSTRACT Innate lymphoid cells (ILCs) play important roles in host defense and inflammation. They are classified into three distinct groups based on their cytokine and chemokine secretion patterns and transcriptome profiles. Here, we show that ILCs isolated from mice can be infected with herpes simplex virus 1 (HSV-1) but that subsequent replication of the virus is compromised. After infection, type 2 ILCs expressed significantly higher levels of granulocyte colony-stimulating factor (G-CSF), interleukin 1α (IL-1α), IL-6, IL-9, RANTES, tumor necrosis factor alpha (TNF-α), CXCL1, CXCL2, CXCL10, CCL3, and CCL4 than infected type 1 or type 3 ILCs. Transcriptome-sequencing (RNA-seq) analysis of the ILCs 24 h after HSV-1 infection revealed that 77 herpesvirus genes were detected in the infected type 3 ILCs, whereas only 11 herpesvirus genes were detected in infected type 1 ILCs and 27 in infected type 2 ILCs. Compared with uninfected cells, significant upregulation of over 4,000 genes was seen in the HSV-1-infected type 3 ILCs, whereas 414 were upregulated in the infected type 1 ILCs and 128 in the infected type 2 ILCs. In contrast, in all three cell types, only a limited number of genes were significantly downregulated. Type 1, type 2, and type 3 ILC-deficient mice were used to gain insights into the effects of the ILCs on the outcome of ocular HSV-1 infection. No significant differences were found on comparison with similarly infected wild-type mice or on comparison of the three strains of deficient mice in terms of virus replication in the eyes, levels of corneal scarring, latency-reactivation in the trigeminal ganglia, or T-cell exhaustion. Although there were no significant differences in the survival rates of infected ILC-deficient mice and wild-type mice, there was significantly reduced survival of the infected type 1 or type 3 ILC-deficient mice compared with type 2 ILC-deficient mice. Adoptive transfer of wild-type T cells did not alter survival or any other parameters tested in the infected mice. Our results indicate that type 1, 2, and 3 ILCs respond differently to HSV-1 infection in vitro and that the absence of type 1 or type 3, but not type 2, ILCs affects the survival of ocularly infected mice. IMPORTANCE In this study, we investigated for the first time what roles, if any, innate lymphoid cells (ILCs) play in HSV-1 infection. Analysis of isolated ILCs in vitro revealed that all three subtypes could be infected with HSV-1 but that they were resistant to replication. The expression profiles of HSV-1-induced cytokines/chemokines and cellular and viral genes differed among the infected type 1, 2, and 3 ILCs in vitro. While ILCs play no role or a redundant role in the outcomes of latency-reactivation in infected mice, absence of type 1 and type 3, but not type 2, ILCs affects the survival of infected mice.
No comment yet.
Scooped by Gilbert C FAURE
June 16, 2019 2:30 PM
Scoop.it!

Researchers discover mechanism by which cells communicate in inflammatory processes

Researchers discover mechanism by which cells communicate in inflammatory processes | Immunology | Scoop.it
A research group from MedUni Vienna and CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences has discovered a new mechanism by which cells communicate in inflammatory processes. This involves endogenous mitochondria released from white blood cells turning into initiators of inflammation. It is as if friends turn into enemies. The results have now been published in the journal Circulation Research.
No comment yet.